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 1 INTRODUCTION 
 
Changes in dietary and lifestyle patterns are the reasons for many diet-related 
diseases, including obesity, diabetes mellitus, cardiovascular disease, 
hypertension, stroke and various forms of cancer. Since the nutritional 
behaviour plays a pivotal factor in their development, the above mentioned 
diseases are partly preventable (Manco et al., 2004). 
 
Diabetes mellitus is one of the most common chronic diseases worldwide. As 
recent study results show the incidence and prevalence are continuously 
increasing. In 2011 366 million people worldwide suffered from diabetes. The 
majority of those (90-95%) were affected by type 2 diabetes (IDF, 2011).  
Beside antidiabetic medication a successful therapy includes the right choice of 
diet and physical activity (ADA, 2008). 
 
The present master thesis was performed within the project DIAPLANT, which 
is a cross-border cooperation project between Austria and Slovakia, funded by 
EU. A human intervention study was performed at the Department of Nutritional 
Sciences at the University of Vienna / Emerging Field "Oxidative Stress and 
DNA Stability". 
The aim of the thesis was to investigate the influence of an eight-week 
intervention with plant oil and vegetables on the fatty acid profile in the plasma 
of type 2 diabetics. The primary objective of this work was to verify the 
compliance of the subjects. Furthermore, the plasma levels of several fatty 
acids between type 2 diabetics, healthy subjects and those with abnormal 
fasting glucose concentrations were compared. The resulting changes due to 
the intervention and the different effects on the various states of health were 
analysed. 
 
Within the DIAPLANT project the influence of the vegetable and plant oil 
intervention on other biochemical biomarkers (e.g. vitamins) were evaluated in 
other theses. 
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 2 DIABETES 
 
 2.1 Definition of diabetes mellitus 
 
Diabetes mellitus or simply diabetes is a group of metabolic diseases 
characterized by high blood glucose levels resulting from defects in the body's 
ability to produce and use insulin. The chronic hyperglycemia is associated with 
long-term damages, dysfunction and failure of several organs and blood vessels 
(ADA, 2012). 
 
When glucose cannot be used for energy production, it accumulates in the 
blood and is excreted by the kidneys as soon as the threshold of 160 to 180 mg 
glucose per 100 ml blood is reached (DGE, 1998). 
 
Since glucose is an important energy source for the cells, a lack of glucose 
leads to failures in energy-, fat- and protein metabolism. The reason of the 
abnormalities is deficient action of insulin on target tissues. Deficient insulin 
action results from inadequate insulin secretion and / or diminished tissue 
responses to insulin at one or more points in the complex pathways of the 
hormone action (DGE, 1998). 
 
When the glucose metabolism derails, hypo- or hyperglycemia occurs, possibly 
leading to secondary complications. 
Symptoms of hypoglycemia include tremor, attacks of sweating, vertigo and 
ravenous appetite. Possible implications are disorientation and 
unconsciousness. 
A hyperglycemia is accompanied by thirst, continual urination and tiredness. If 
the fettle remains untreated, complications in the blood vessels of eyes, 
kidneys, legs and the heart or the life-threatening diabetic coma might occur 
(DGE, 1998). 
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 2.2 Epidemiology  
 
Diabetes mellitus is one of the most common chronic diseases worldwide, with 
a continuously increasing number of prevalence and incidence. 
According to the IDF in 2011 366 million people were suffering from type 2 
diabetes, representing 8.3% of the global adult population. Forecasts assume 
that this number will increase to 552 million people by 2030 (figure 1). This 
equates to approximately three new cases every ten seconds. The IDF expects 
that the number of diabetics will increase to 64 million in Europe in 2030 (figure 
1). In Austria about 571.000 people at the age of 20-79 years currently suffer 
from diabetes, which is estimated to increase to 717.000 by 2030. 
 
 
 
Figure 1: The number of people with diabetes by 2011 and 2030 (IDF, 2011) 
 
 
4 
 
More than 80% of people with diabetes live in low- and middle-income 
countries. In 2011 the Middle East and North Africa Region had the highest 
prevalence of adults with diabetes (11.0%), whereas the prevalence in Europe 
was the lowest (6.7%) (figure 1). In 2030 the number of African people suffering 
from diabetes will almost double to 28 million compared to 14,7 million in 2011. 
Compared to Europe the increase in Africa in 2030 will be four times as high 
(IDF, 2011). 
 
 
 2.3 Types of diabetes 
 
 2.3.1 Type 1 diabetes  
 
Type 1 diabetes accounts for 5-10% of diabetics and is usually diagnosed in 
children and young adults, therefore previously known as juvenile diabetes 
(DGE, 1998). Type 1 diabetes results from a cellular-mediated autoimmune 
destruction of the b-cells of the pancreas, so that initially too little and later on 
no insulin at all is produced (ADA, 2012). Therefore these diabetics depend on 
extrinsic insulin (DGE, 1998). Autoimmune destruction of b-cells has multiple 
genetic predispositions and is also related to environmental factors that are still 
poorly understood (ADA, 2012). 
 
 2.3.2 Type 2 diabetes 
 
Type 2 diabetes is the most common form of diabetes, accounting for 90-95% of 
all diabetics. It encompasses individuals who have insulin resistance and 
usually have relative insulin deficiency. Autoimmune destruction of b-cells does 
not occur (ADA, 2012). 
The risk of developing this form increases with age, obesity and lack of physical 
activity. It is often associated with a genetic predisposition. However, the genetic 
background is complex and not clearly defined yet (DGE, 1998). 
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In type 2 diabetes either the body does not produce enough insulin or the cells 
are resistant to insulin. As the disease develops unapparent it is often only 
revealed by chance. At that point the body produces average amounts of 
insulin, which cannot operate properly because its emission is delayed (DGE, 
1998). The higher blood glucose levels would be expected to result in even 
higher insulin values if their b-cell function is normal. But in these patients 
insulin secretion is defective and insufficient to compensate for insulin 
resistance (ADA, 2012). 
Most often overweight and physical inactivity promote type 2 diabetes. Thus a 
normalization of body weight and the right choice of food help to regularise 
blood sugar levels. In some cases a further treatment with antidiabetic 
medication or insulin is necessary (DGE, 1998). 
 
 2.3.3 Gestational Diabetes Mellitus 
 
Pregnant women with high blood glucose levels during pregnancy have 
established gestational diabetes. The development remains unclear, but it is 
hypothesized that placenta hormones which are important for the development 
of the baby block the function of the mother's insulin in her body. Due to this 
insulin resistance, the mother's body can hardly use insulin. Although insulin 
does not cross the placenta, glucose and other nutrients are able to. Extra 
blood glucose passes the placenta, resulting in high blood glucose levels in the 
baby. 
This causes the baby's pancreas to produce extra insulin. Since the baby is 
getting more energy than it needs to grow and develop, the extra energy is 
stored as fat. This can lead to macrosomia.  
Babies with macrosomia face health problems of their own, including damage to 
their shoulders during birth. Because of the extra insulin produced by the 
babies' pancreas, newborns may have very low blood glucose levels at birth 
and are also at higher risk for breathing problems. Babies with excessive insulin 
production are at higher risk for developing obesity and type 2 diabetes (ADA, 
2004). 
6 
 
 2.4 Clinical diagnostics 
 
In order to diagnose diabetes mellitus glucose levels are measured in the blood 
(Leitzmann et al., 2009). It is important that higher levels are measured at least 
at two different days. The normal fasting blood glucose concentration in the 
plasma accounts for ≤ 100 mg/dl (≤ 5.6 mmol/l) (Roden, 2009). 
 
The diagnostic criteria are (ADA, 2012): 
 
· HbA1C ≥ 6.5% 
  or 
· Fasting plasma glucose ≥ 126 mg/dl (≥ 7.0 mmol/l) 
  or 
· 2-h plasma glucose ≥ 200 mg/dl (≥ 11.1 mmol/l): The test should use a 
glucose load containing the equivalent of 75 g anhydrous glucose 
dissolved in water. 
  or 
· A random plasma glucose ≥ 200 mg/dl (≥ 11.1 mmol/l) when classic 
symptoms of hyperglycemia are present (ADA, 2012). 
 
 
 2.5 Risk factors for type 2 diabetes 
 
As mentioned before type 2 diabetes is nowadays the most common form of 
diabetes mellitus. More than 90% of all cases of diabetes mellitus are assigned 
to this type. Type 2 diabetes is a heterogeneous disease: The focus of the 
pathophysiology is on the one hand a disorder of the impact of insulin on the 
target cells (insulin resistance) and on the other hand a failure of insulin 
secretion due to one or more so far not exactly known defects of the b-cells in 
the pancreas. At the beginning a resistance to insulin, which is caused and 
encouraged by many lifestyle factors, will be initially compensated by increased 
pancreatic insulin secretion. When the b-cells, probably due to genetic defects, 
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are no longer able to keep increased secretion of insulin, this results in the final 
manifestation of the disease. 
 
Lifestyle factors have a major impact on the development and progression of 
type 2 diabetes. Important risk factors to an impaired glucose tolerance and 
type 2 diabetes are an age of more than 45 years, overweight and obesity (BMI 
> 25 kg/m²), a positive family history, physical inactivity, hypertension (140/90 
mm Hg) and dyslipoproteinemia (HDL-cholesterol < 40 mg/dl, triglycerides > 
250 mg/dl).  
However, the most significant risk factor of the manifestation of type 2 diabetes 
is by far obesity. Even a weight gain during adulthood increases the risk of 
diabetes substantially (Hauner and Schulze, 2011).  
People with impaired glucose tolerance, which is defined as a fasting blood 
glucose level < 126 mg/dl and a 2-hour value between 140 and 199 mg/dl after 
a glucose load with 75 g of dextrose, have particularly high risks for diabetes 
(DGE, 2006). 
Prevention studies have shown that intensive lifestyle modification (reducing 
weight, reducing total intake of fat and intake of saturated fat, increasing intake 
of fibre and physical activity) of these people can reduce the risk of diabetes by 
58% over a period of three years. The lifestyle intervention was even 
significantly more effective than Metformin, which reduced the risk of diabetes 
by 31% (Tuomilehto et al, 2001; Knowler et al, 2002). 
 
 
 2.6 Nutrition therapy in type 2 diabetes 
 
The aims of a nutrition therapy in diabetes are to achieve normal blood glucose 
and HbA1c levels, improved blood lipid levels, normal blood pressure, normal 
body weight and the prevention of complications of diabetes. All these factors 
can be positively influenced by certain dietary measures. Diabetics are 
recommended to keep a diet that meets the basic outlines of the 
recommendations for healthy adults (ADA, 2008; DGE, 2008). 
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On the basis of nutrients the following measures are recommended by the DGE 
(2008): 
 
· Carbohydrate intake can account for 45-60% of total energy.  
· Total fat intake should not exceed 35% of the total energy; saturated and 
trans fatty acids together should be under 10% of total daily energy 
intake. 
· Patients without signs of nephropathy can consume 10-20% of the total 
energy in form of proteins. 
· Fibre intake should ideally be above 40 g/day. 
· The intake of free sugars should be moderate (up to 50 g/day); free 
sugar intake should not exceed a total of 10% of the total energy. 
 
The nutritional interventions at the level of food include: 
 
· Eating enough dietary fibre and foods rich in vitamins 
· Daily consumption of fruits, vegetables, salad, legumes and whole grains 
· Two or three servings of fish per week, preferably fat fish 
· Avoiding the consumption of fatty meats, cheeses, chocolate, cakes and 
pastries 
· Choosing low-fat dairy products 
· Using oils that are rich in monounsaturated fatty acids for cooking 
instead of animal fats 
· Limiting the daily amount of salt 
· Consuming alcoholic beverages moderately; due to the risk of 
hypoglycemia patients should be careful with consuming alcoholic 
beverages after sports and additional physical activity (DGE, 2008). 
 
Being active is another part of living healthy and managing diabetes. Any type 
of physical activity can help to lower blood glucose (ADA, 2008). 
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 2.7 Insulin resistance and sensitivity 
 
 2.7.1 Insulin resistance 
 
Insulin resistance is the inability of a known quantity of insulin to increase 
glucose uptake and utilisation in an individual as much as it does in a normal 
population (Lebovitz, 2001). 
Due to the diminished ability of cells to respond to the action of insulin in 
transporting glucose from the bloodstream into muscle and other tissues the 
person's body produces larger quantities of insulin to maintain normal levels of 
glucose in the blood. As long as the pancreas can produce enough insulin to 
overcome this resistance, blood glucose levels remain normal. Once the 
pancreas is no longer able to do this, blood glucose starts to rise, initially after 
meals, eventually even in the fasting state. This is usually the time point when 
type 2 diabetes is diagnosed (Lee, 2010). 
 
There are several mechanisms suggested as possible causes for the 
development of insulin resistance. These include:   
ñ genetic abnormalities of proteins of the insulin action cascade  
ñ fetal malnutrition 
ñ increase in visceral adiposity (Lebovitz, 2001). 
 
Insulin resistance occurs as part of a cluster of cardiovascular-metabolic 
abnormalities commonly referred to as "The Metabolic Syndrome". This cluster 
may lead to the development of atherosclerosis, hypertension or polycystic 
ovarian syndrome (Lebovitz, 2001; Wilcox 2005). 
 
Increased dietary fat intake is an important contributor to the development of 
insulin resistance. The underlying mechanisms could be the decreasing glucose 
uptake in the muscles and the reduction of the insulin-stimulated insulin 
receptor substrate (IRS)-1 tyrosine phosphorylation and IRS-1-associated 
phosphatidylinositol 3-kinase activity (Holness et al., 2003). 
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 2.7.2 Insulin sensitivity 
 
Insulin sensitivity is the sensitivity of the insulin receptors towards insulin. It is 
measured by the insulin sensitivity index and the glucose-clamp technique 
(Heinze et al., 2002).  
The former measures the ability of endogenous insulin to reduce glucose in 
extracellular fluids by inhibiting glucose release from the liver and stimulating 
the peripheral consumption of glucose. The latter measures the effect of 
changes in insulin concentration on glucose clearance, which is a fictional 
measure for the elimination of glucose out of the blood plasma (McGraw-Hill 
Concise Dictionary of Modern Medicine, 2002). 
 
 
 2.8 Carbohydrate intake and the risk of diabetes 
 
Carbohydrates can influence the secretion and impact of insulin in different 
ways, depending on their quantity and composition. A rapid increase in the 
blood glucose concentration due to short-chain carbohydrates causes not only a 
fast and strong insulin secretion but can also exert pro-oxidative and pro-
inflammatory effects (Riccardi et al, 2008). 
 
Conversely, complex carbohydrates lead to a moderate increase in blood 
glucose concentration, which can improve insulin resistance: Consumption of 
soluble dietary fibre reduces postprandial glucose responses after 
carbohydrate-rich meals, as well as lowering total and LDL-cholesterol levels 
(Jenkins et al., 2000). However, it is mainly the consumption of insoluble cereal 
dietary fibre and whole grains that is associated with reduced risk of type 2 
diabetes (de Munter et al., 2007; Schulze et al., 2007). 
An increased intake of total dietary fibre was inversely associated with markers 
of insulin resistance in several studies (Pi-Sunyer, 2005). Investigating different 
soluble and insoluble dietary fibre in randomized controlled intervention studies 
yielded in mixed results. Consumption of wheat bran for three months did not 
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change fasting glucose and glycated hemoglobin levels in diabetic subjects 
(Jenkins et al., 2002). Consumption of insoluble dietary fibre increased the 
whole body glucose disposal (Robertson et al., 2005).  
Since insulin resistant subjects are more likely to eventually develop diabetes, 
improved insulin sensitivity could be a relevant factor contributing to reduce the 
risk for diabetes in subjects consuming diets high in insoluble dietary fibre 
(Weickert and Pfeiffer, 2008). 
 
Furthermore a high proportion of soluble dietary fibre and a low glycemic index 
diet have beneficial effects on both the glucose and lipid metabolism. The 
underlying mechanism is probably a delay of the intestinal glucose absorption. 
Thus the type and amount of carbohydrates and dietary fibre as part of a mixed 
meal have considerable influence on the postprandial glucose and insulin 
responses (Riccardi et al, 2008). 
 
The postprandial rise of the blood glucose concentration seems to control not 
only the insulin secretion significantly, but also influences many steps in the 
utilization of glucose, which is under the control of insulin and other hormones. 
However, what remains unclear is the role of the absolute amount of 
carbohydrate intake in connection with the risk for type 2 diabetes (Hauner and 
Schulze, 2011). 
 
 
 2.9 Fat consumption and the risk of type 2 diabetes 
 
The primary objective of a lifestyle and nutrition intervention is the removal of 
hyperglycemia as a risk factor for micro- and macroantiopathic complications. 
Therefore relations between fat consumption and insulin resistance are to the 
fore of the assessment of evidence (Hauner and Schulze, 2006). 
There are further biological mechanisms that could produce an effect of fatty 
acids on the risk of diabetes. Accumulation of triglycerides in the muscle tissue 
reduces the insulin-stimulated glucose absorption and glucose oxidation, 
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whereas the accumulation of triglycerides in b-cells of the pancreas leads to a 
reduction of insulin secretion (Manco et al., 2004). Furthermore chronic 
exposure to high levels of lipids initially boosts the insulin response in 
hyperinsulinemic conditions as a result of a glucose load (Warnotte et al., 1994). 
Later, it selectively desensitises the b-cell to glucose and causes b-lipotoxicity 
(Capito et al., 1992). 
In order to normalise the blood or tissue lipid profile a β-cell compensation for 
insulin resistance may be adapted (Marchesini et al., 2001). Though, β-cell 
compensation may be inadequate during the development and progression of 
type 2 diabetes, since it is insufficient to maintain blood glucose and blood and 
tissue lipid levels within the normal physiological range (Kubota et al., 2000). 
The b-cell response depends on the chain length of fatty acids and on their 
degree of saturation (Stein et al., 1997). Thus, for any given level of glucose, 
insulin secretion will be greatly influenced by free fatty acid (FFA) circulating 
levels and also by the percentage of unsaturation of the fatty acids. The 
mechanisms leading to a decrease in insulin secretion are still unclear. The 
decrease is likely to occur via other mechanisms such as induction of 
glucokinase and insulin gene expression (Gremlich et al., 1997). 
On the contrary, polyunsaturated fatty acids (PUFA), in particular w-3 fatty 
acids, could improve the insulin sensitivity (Manco et al., 2004). Eicosanoids, 
which are metabolic products of PUFA, could influence the activity of insulin in 
muscle cells (Pegorier et al. 2004). Thus PUFA could immediately contribute to 
the regulation of enzymes of lipolysis and lipogenesis in muscle cells (Manco et 
al., 2004). 
 
Although data of animal experiments mostly confirm these assumptions (Hu et 
al. 2001; Rivellese and Lilli, 2003), several investigations in human subjects 
(Vessby et al. 2001, Salméron et al. 2001, Van Dam et al. 2002) failed to yield 
conclusive results regarding the effects of dietary saturated fatty acids (SFA) 
and PUFA on insulin sensitivity and secretion, because many confounding 
dietary and non-dietary factors directly affect insulin sensitivity, such as physical 
activity, smoking habits or amount of fibres in the diet. (Manco et al., 2004). 
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 2.9.1 Impacts of total fat 
 
An increasing body of evidence suggests that lipid overflow causes excessive 
storage of triglycerides (TG) in non-adipocyte cells, leading to impairment of 
cellular metabolism through the phenomenon of lipotoxicity (Manco et al., 
2004). 
 
Muscle and hepatic insulin resistance are two major defects of non-insulin-
dependent diabetes mellitus. Since dietary factors may be important in the 
etiology of insulin resistance, Kraegen et al. (1991) studied progressive 
changes in the development of high-fat-diet-induced insulin resistance in tissues 
of adult male Wistar rats. Muscle triglyceride accumulation due to fat feeding 
was not significantly different after three days, but had doubled after three 
weeks in red muscle cells compared to starch-fed controls. Fat feeding 
significantly reduced suppressibility of hepatic glucose output by insulin. After 
three weeks high-fat-fed animals had developed significant glucose intolerance. 
The authors concluded that fat feeding induces insulin resistance in liver and 
adipose tissue before skeletal muscle with early metabolic changes favoring an 
oversupply of energy substrate to skeletal muscle relative to metabolic needs. 
This may generate later muscle insulin resistance (Kraegen et al., 1991). 
 
Conclusion: 
It lacks studies investigating the effect of the total fat intake on insulin sensitivity 
and glucose metabolism in patients with type 2 diabetes mellitus. It is important 
that a reduction in fat intake is not accompanied by additional dietary 
modifications. Therefore the relative content of the individual fatty acid fractions 
should remain unchanged (Hauner and Schulze, 2006). The Joint FAO/WHO 
Expert Consultation on Fats and Fatty Acids in Human Nutrition (2008) defines 
the relationship between the total fat intake and the risk for diabetes as 
insufficient. 
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 2.9.2 Impacts of w-3 fatty acids 
 
Controlled intervention studies in subjects with type 2 diabetes could not find an 
improvement in insulin sensitivity after supplementation with w-3 fatty acids 
(Rivellese and Lilli, 2003; Storlien et al., 1996). Therefore Mostad et al. (2006) 
investigated short-term (one week) and longer-term (nine weeks) effects of w-3 
fatty acids in subjects with type 2 diabetes which had no hypertriglyceridemia by 
supplementing fish oil, while participants of the control group got the same 
amount of corn oil (20 ml/day for nine weeks, given as liquid). Concentrations of 
both eicosapentaenic acid (EPA) and docosahexaenic acid (DHA) increased in 
adipose tissue and plasma phospholipids in the fish oil group. Opposite to this 
the ratio of w-6 to w-3 fatty acids decreased during the intervention. The 
increased intake of linoleic acid (LA) in the corn oil group had no effect on the 
fatty acid profile in plasma phospholipids and adipose tissue. However, the LA 
decreased in the phospholipids in the fish oil group. 
The average daytime concentrations as well as the fasting concentrations of 
blood glucose were higher in the fish oil group after nine weeks of intervention. 
Glycated hemoglobin was not affected by the intervention with w-3 fatty acids. 
Nevertheless, glucose utilisation, a measure of insulin sensitivity, was lowered 
in the fish oil group. On the other hand the insulin secretion did not significantly 
differ but tended to be higher in the fish oil group. Furthermore, w-3 fatty acids 
first (after one week) decreased and later on increased the fatty acid utilisation. 
The authors conclude that a high intake of fish oil (20 ml/day) has moderate but 
negative effects on glycemia like increased blood glucose concentrations and 
decreased insulin sensitivity (Mostad et al., 2006). 
 
The beneficial effects of w-3 fatty acids on insulin action are well documented in 
animals but not in humans (Hu et al. 2001; Rivellese and Lilli, 2003). Giacco et 
al. (2007) evaluated whether a supplementation with w-3 fatty acids is able to 
modulate insulin sensitivity and secretion in healthy individuals. Subjects were 
randomised into groups consuming a diet rich in either saturated or 
monounsaturated fatty acids. Within these two groups there was a second 
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randomisation to fish oil (3.6 g w-3 fatty acids/day) or placebo. EPA and DHA 
concentrations increased in the subjects supplemented with w-3 fatty acids. In 
the placebo groups a decrease in these long-chain PUFA could be observed. 
Insulin sensitivity did not change in any of the four groups as well as insulin 
secretion was not affected by supplementation with w-3 fatty acids in both diets. 
Consequently, the disposition index, which is an integrated parameter of 
glucose tolerance accounting for insulin sensitivity and secretion, was not 
affected by w-3 fatty acid supplementation in either diet.  
The study showed that a supplementation with w-3 fatty acids was not able to 
modulate insulin action, insulin secretion disposition index or glucose tolerance, 
regardless of the fatty acid composition of the background diet. However, the 
authors assume that the inverse relation between w-3 fatty acids and the 
incidence of type 2 diabetes has to be explained by other effects of w-3 fatty 
acids (Giacco et al., 2007). 
 
In the KANWU study Vessby et al. (2001) examined whether a change in the 
dietary fat quality influences insulin sensitivity and if so, whether these 
supposed effects were affected by addition of w-3 fatty acids. Experimental 
studies have already indicated that fat quality could affect insulin sensitivity 
(Storlien et al., 1996). However, this could not be shown in human intervention 
studies.  
The healthy study population was divided into two groups: One group received 
a diet containing a high proportion of SFA (SFA diet), the other one received a 
diet containing a high proportion of monounsaturated fatty acids (MUFA diet). 
Within these two groups there was another splitting into those who obtained 
capsules containing fish oil (3.6 g w-3 fatty acids/day for 90 days) and those 
who received placebo capsules containing the same amount of olive oil.  
The study could show that a shift from SFA to MUFA improves insulin sensitivity, 
which was 12.5% lower on the SFA diet and 8.8% higher on the MUFA diet.  
Nevertheless the beneficial effects of the MUFA diet on insulin sensitivity could 
not be seen when the fat intake was high (> 37% of total energy intake).  
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Improvements in insulin sensitivity were only observed in subjects with a lower 
fat intake. Hence not only the quality but also the proportion of total fat in a diet 
is relevant. The addition of w-3 fatty acids did not affect the insulin sensitivity in 
both diets. The authors suggest that it will take years to see a change in insulin 
actions as effects of w-3 fatty acids. Furthermore the ratio of w-6: w-3 of skeletal 
muscle cell membranes might be important to determine the insulin sensitivity. 
Moreover the addition of w-3 fatty acids may affect the insulin sensitivity only in 
people with very low initial concentrations of w-3 fatty acids. The insulin 
secretion was not affected by a change of dietary fat quality (Vessby B. et al, 
2001). 
 
Beside other foods nuts are rich in unsaturated fatty acids, vitamin E and fibre. 
What is unique about walnuts is their high content in both w-6 and w-3 fatty 
acids. Since unsaturated fatty acids and fibre may improve plasma lipids, 
Almario et al. (2001) investigated the effects of walnut consumption in subjects 
with high plasma total cholesterol (> 5.17 mmol/l) and TG (> 2.26 mmol/l) 
concentrations. On the basis of two different background diets (habitual diet and 
low-fat diet) they wanted to determine whether supplementation of 48 g walnuts 
(3.3 g w-3 fatty acids) or restriction with other dietary fats was responsible for 
the improvements in plasma lipids.  
The addition of walnuts to both diets increased LA and a-linolenic acid (ALA) 
and decreased arachidonic acid (AA) concentrations in the plasma, whereas 
concentrations of EPA and DHA did not change. The authors suggest these 
findings as a result of the competition between LA and ALA for the d-6-
desaturase. 
In summary this study shows that walnuts, which are a rich source of both w-3 
and w-6 fatty acids, have different metabolic effects on weight, plasma fatty acid 
composition, plasma lipids and apoproteins than the individual effects of either 
w-3 or w-6 fatty acids (Almario et al., 2001). 
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Conclusion: 
The pictured intervention studies provide convincing evidence that long-chain w-
3 fatty acids have no effect on the long-term blood glucose control and the 
insulin sensitivity in diabetic patients. Thus the available data appear to be 
insufficient for recommendations concerning the supplementation with w-3 fatty 
acids in subjects with type 2 diabetes (Hauner and Schulze, 2006).  
 
 2.9.3 Impacts of Saturated Fatty Acids 
 
Several studies have been conducted to demonstrate that a high fat intake, 
particularly if rich in SFA, is associated with impaired insulin sensitivity and 
secretion and the development of type 2 diabetes (Lovejoy, 1999; Marshall et 
al., 1997). However, no large modification of the type of fatty acids in the diet 
(saturated vs. unsaturated) is needed in order to prevent the adverse effect of 
dietary saturated fat on insulin action (Kraeger et al., 1991; Jucker et al., 1999). 
 
Reducing the intake of SFA on a 10% maximum of total energy intake was part 
of the intervention in the Finnish Diabetes Prevention Study and the American 
Diabetes Prevention Program (Tuomilehto et al., 2001; Diabetes Prevention 
Program Research Group, 2002). In both studies the risk of developing diabetes 
was reduced by 58%. Due to the multifactorial nature of the studies (weight-
commissioning, physical activity, changes in other nutritional parameters, 
especially the total fat intake) an allocation of the observed effect to the 
changes in SFA intake is not possible (Hauner and Schulze, 2006). 
In the San Luis Valley diabetes study subjects with incident diabetes mellitus did 
not have a significantly higher intake of SFA than adults with normal glucose 
tolerance (Marshall et al., 1994). Even in the Iowa Women's Study no 
relationship between SFA intake and diabetes risk was observed. However, the 
replacement of SFA with PUFA was associated with a significantly lower risk of 
developing diabetes (Meyer et al., 2001). In the Health Professionals Follow-up 
Study no relationship between SFA and the risk for diabetes could be observed 
(Van Dam et al., 2002). In the Kuopio Ischaemic Heart Disease Risk Factor 
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Study the intake of SFA in individuals who developed diabetes mellitus was not 
significantly different from individuals staying healthy (Laaksonen et al., 2002). 
In Wistar-rats fed with high saturated fat peripheral insulin resistance was 
accompanied by increased insulin secretion such that glucose tolerance was 
maintained (Chalkley et al., 2002). This finding confirms the concept that insulin 
resistance generates hyperinsulinemia (Holness et al., 2003).  
Holness et al. (2003) substituted a small amount of dietary lipid with long-chain 
w-3 fatty acids during four weeks of high-saturated fat feeding. They 
investigated the relationship between amelioration of insulin resistance and 
glucose-stimulated insulin secretion. They demonstrate that, despite dietary 
delivery of saturated fat, this manipulation prevents insulin resistance and 
reverses insulin hypersecretion in response to glucose in vivo.   
Effects of long-chain w-3 fatty acid supplementation to lower the insulin 
secretion were also observed in perifused islets suggesting a direct effect on 
islet function. However, this supplementation led to hepatic insulin resistance. 
The data demonstrate that the insulin response to glucose is suppressed to a 
greater extent than insulin sensitivity is enhanced by intake of a high SFA diet 
with long-chain w-3 fatty acids. Furthermore, reduced insulin secretion indicates 
that long-chain w-3 fatty acids directly impair the b-cell response to SFA. 
Therefore insulin secretion cannot be augmented to normalise glucose 
tolerance. Moreover, b-cell compensatory hypersecretion represents a response 
to insulin resistance. 
It seems reasonable that peripheral insulin resistance and increased insulin 
secretion during high SFA feeding arise simultaneously. The reason could be a 
common action on skeletal muscle and the pancreatic b-cell that is counteracted 
by small quantities of dietary long-chain w-3 fatty acids (Holness et al., 2003). 
 
Conclusion: 
Cohort studies on the question of whether there is an association between SFA 
intake and the risk for type 2 diabetes mellitus could not confirm this in the 
majority (Meyer et al., 2001; Van Dam et al., 2002). The Joint FAO/WHO Expert 
Consultation on Fats and Fatty Acids in Human Nutrition (2008) rates the 
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relationship between SFA and the risk for diabetes as possible. However, cohort 
studies allow us to conclude that the exchange of SFA by PUFA lowers the risk 
for type 2 diabetes (Hauner and Schulze, 2006). 
 
 2.9.4 Impacts of Monounsaturated Fatty Acids 
 
Results of the Finnish and Dutch cohorts of the Seven Countries Study showed 
that men with newly diagnosed diabetes mellitus had a higher MUFA intake at 
baseline than men with normal glucose tolerance (Feskens et al., 1995).  
In the San Luis Valley Diabetes Study people with glucose intolerance and 
developing diabetes mellitus had even consumed a larger amount of MUFA 
than those who returned to a normal glucose tolerance after the observation 
period (Marshall et al., 1994). In the more recent cohort studies [Iowa Women's 
Study (Meyer et al., 2001), Nurses' Health Study (Salmeron et al., 2001), Health 
Professionals Follow-up Study (Van Dam et al., 2002), Kuopio Ischaemic Heart 
Disease Risk Factor Study (Laaksonen et al., 2002) and the Women's Health 
Study (Song et al., 2004)] no association between the intake of MUFA and the 
risk for diabetes could be observed. 
 
Conclusion: 
In cohort studies (Meyer et al., 2001; Salmeron et al., 2001; Van Dam et al., 
2002; Laaksonen et al., 2002; Song et al., 2004) no association was observed 
between MUFA intake and risk for diabetes. The Joint FAO/WHO Expert 
Consultation on Fats and Fatty Acids in Human Nutrition (2008) rates the 
connection between MUFA and the risk for diabetes as insufficient. 
 
 2.9.5 Impacts of Polyunsaturated Fatty Acids 
 
In order to examine the effects of safflower oil versus fish oil feeding on 
intramuscular glucose metabolism Jucker et al. (1999) pair-fed rats on diets 
consisting of 59% safflower oil, 59% menhaden fish oil or 59% carbohydrate 
(control) in calories.  
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The insulin resistance in skeletal muscle associated with chronic safflower oil 
feeding could primarily be attributed to a reduction in glycolysis. By contrast, 
fish oil feeding had no effect on any of the major intramuscular pathways of 
glucose metabolism. Additionally, FFA and ketone oxidation were greater in the 
safflower oil group than in the control or fish oil group. 
These data suggest that the elevated intramuscular TG observed in the rats fed 
safflower oil correlates with increased fat oxidation. Moreover the protective 
effect of fish oil feeding may occur through its ability to limit TG deposition in 
skeletal muscle. However, a relative increase in fat oxidation in the fish oil group 
versus controls during hyperinsulinemic conditions could not be observed. 
Thus, the protective effect of fish oil on insulin-stimulated muscle glucose 
disposal seems to occur via a relative reduction of FFA oxidation compared to 
the rats fed safflower oil. Possibly this is a result of lowered intramuscular TG 
and FFA availability. 
The results demonstrate that the decreased release of glucose in muscle cells 
in rats fed with safflower oil can be primarily ascribed to a reduction in 
glycolysis, which is associated with decreased intramuscular pyruvate oxidation 
and increased fat oxidation. Furthermore chronic fish oil feeding saves the 
muscle from becoming insulin resistant by lowering intramuscular TG availability 
for oxidation relative to safflower oil feeding (Jucker et al., 1999). 
 
In the San Luis Valley Diabetes Study no relationship was found between the 
PUFA intake and the development of diabetes mellitus. Subjects who developed 
diabetes mellitus did not have a different intake of PUFA compared to those who 
kept their impaired glucose tolerance (IGT) or those who returned to a normal 
glucose tolerance (Marshall et al., 1995).  
After an observation period of 11 years in the Iowa Women's Health Study a 
negative relationship between the PUFA intake and the incidence of diabetes 
was found, but it did not reach statistical significance. However, the replacement 
of SFA with PUFA was associated with a significantly lower risk (Meyer et al., 
2001).  
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In the Nurses’ Health Study an increased proportion of PUFA in the diet 
correlated negatively with the risk for diabetes (Salmeron et al., 2001). In the 
Kuopio Ischaemic Heart Disease Risk Factor Study the PUFA intake in subjects 
who developed diabetes mellitus was not significantly different to healthy 
staying individuals. Moreover the PUFA content in the serum was no significant 
predictor for the development of a reduced glucose tolerance or diabetes 
mellitus (Laaksonen et al., 2002). 
 
Conclusion: 
Altogether studies on the role of PUFA in the prevention of type 2 diabetes are 
inconsistent, but assume that a higher PUFA intake, especially as replacement 
for SFA, is associated with a reduced risk for type 2 diabetes (Hauner and 
Schulze, 2006). Additionally, according to the Joint FAO/WHO Expert 
Consultation on Fats and Fatty Acids in Human Nutrition (2008), there is 
convincing evidence that PUFA, when replacing SFA, reduce the risk for 
coronary heart diseases. Furthermore the association between PUFA and a 
reduced risk for diabetes is seen as possible (Joint FAO/WHO Expert 
Consultation on Fats and Fatty Acids in Human Nutrition, 2008). 
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 3 FATTY ACIDS 
 
 3.1 General Facts 
 
Fatty acids are saturated or unsaturated aliphatic monocarbon acids 
(Vostrowsky, 2005). The most common naturally occurring forms are 
unbranched with an even number of C atoms, since they are synthesised by C2-
units (Miebach, 2008). 
 
SFA are aliphatic monocarbon acids with the general chemical formula CnH2n+1-
COOH (n representing the amount of carbon atoms without the C of the 
carboxyl group). 
Unsaturated fatty acids are fatty acids with the general chemical formula  
CnH2n-1,3,5-COOH and having at least one double bond in their chain. They are 
known as mono and poly unsaturated fatty acids.  
Unsaturated fatty acids are named after position and number of double bonds. 
Their specific name arises from the position of the carbon atom of the methyl 
group, which is opposite to the carboxyl group at the distal end of the chain. 
This carbon atom is also referred to as the omega carbon atom (abbreviated 
with w or n). When indicating the position of the double bond the omega carbon 
atom is the starting point for counting and is therefore provided with number 1 
(Doenecke et al., 2005). 
 
The common SFA in the diet are palmitic and stearic acids - which are present 
in lard, mutton and beef - and lauric and myristic acids, which are present in 
coconut and palm oils. The major sources of MUFA are olive and rapeseed oil, 
which contain oleic acid (Manco et al., 2004). 
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 3.2 Polyunsaturated fatty acids (PUFA) 
 
 3.2.1 Biosynthesis of PUFA 
 
PUFA are of major importance for development and maintenance of health of 
humans and animals. The double bonds are hereby in the cis-configuration and 
mostly isolated, which means that they are separated by a CH2-group 
(Doenecke et al., 2005) 
Since double bonds at the w-3 and w-6 position can only be inserted by plant 
enzymes, fatty acids with double bonds at these positions belong to the 
essential fatty acids (LA and ALA). The requirements of PUFA like LA (starting 
compound of the w-6 fatty acid family) or ALA (starting compound of the w-3 
fatty acid family) therefore have to be covered from animal and vegetable 
sources (Bitsch and Bitsch, 2010; Löffler, 2007). 
 
Due to structural differences there is no possibility to convert w-3 into w-6 fatty 
acids and vice versa. Nevertheless, conversions within the w-3 and w-6 fatty 
acid family can be followed by elongation of the chain and the implementation of 
further double bonds, called desaturation (Fiebig, 2010). 
 
 3.2.2 Elongation of the chain 
 
The elongation of LA to ALA and further happens by a number of different 
desaturases (d-6-, d-5- and d-4-desaturase). These enzymes implement a new 
double bond between the carboxyl terminus and the already existing double 
bond (Rehner and Daniel, 2010). In the course of this process the position of 
the double bonds before the w-9 C-atom remains unchanged. This is the reason 
why the w-notation is suitable to track the paths of polyunsaturated fatty acids in 
the metabolism (Doenecke et al., 2005). Onwards there are further steps of 
elongation, whereas two carbon atoms are added each time. Thereby it 
becomes important that both LA and ALA compete for the same enzymes, 
namely the d-4- and d-6-desaturase (Figure 3). However, both enzymes prefer 
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w-3 fatty acids to w-6 fatty acids (Rehner and Daniel, 2010). The conversion 
from ALA to EPA is estimated to be 10 to 15 %, to DHA at 4% (Trautwein, 1999). 
 
 3.2.3 Eicosanoids 
 
Eicosanoids are a group of autocrine and paracrine acting signalling substances 
that arise from C20-fatty acids and emerge in most animal tissues.  
As mediators they affect many physiological processes and modulate hormonal 
and other signals. Additionally they are essentially involved in the development 
of inflammation. Thus the metabolism of eicosanoids is an important working 
point of medication (Doenecke et al., 2005). 
Eicosanoids are produced from EPA or AA. EPA and DHA are formed by ALA, 
whereas the w-6 fatty acids dihomo-g-linolenic acid and AA are synthesised 
from LA (Figure 2) (Biesalski and Grimm, 2011). 
 
 
  w-3    w-6   
  18:3 ALA  essential  18:2 LA   
    d-6-desaturase     
  18:4    18:3   
    Elongase     
  20:4    20:3   
Series 3    d-5-desaturase    Series 2  
prostanoids  20:5 EPA    20:4 AA  prostanoids 
Series 5    Elongase    Series 4 
leukotrienes  22:5    22:4  leukotrienes 
    d-4-desaturase     
  22:6 DHA    22:5   
Figure 2: Synthesis of eicosanoids (modified after De Caterina et al., 2007) 
 
 
The eicosanoids derived from AA, including series 2 prostanoids and series 4 
leukotrienes, are more inflammatory than those produced from EPA, which are 
series 3 prostanoids and series 5 leukotrienes (Figure 3) (Calder, 1998). Thus a 
shift to a diet rich in w-3 fatty acids can reduce inflammatory processes (De 
Caterina et al., 2007). 
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 3.2.4 Sources of PUFA 
 
PUFA are fundamental components of phospholipids in cell membranes and the 
source for the synthesis of eicosanoids (De Caterina et al., 2007).  
The prevalent source of w-3 fatty acids in the diet are plant oils and fish. Some 
seeds, for example those of cereals, cotton, safflower and soy beans are rich in 
ALA. Linseed oil and soya oil are particularly rich in ALA, whereas safflower oil 
has the highest content of LA of all plant oils with 75-80%, followed by sunflower 
oil (up to 63%) and hemp oil with 50-70%.  
Fatty fishes like salmon, mackerel and herring are the best sources of EPA and 
DHA. Other minor sources are nuts, seeds, egg yolk, some fruits, vegetables 
and poultry meat (Heckel, 2009). The fatty acid pattern of some vegetable oils is 
given in table 1. 
 
 
Table 1: Fatty acid profile of different plant oils (modified after Fiebig HJ, 2011) 
percent by weight, based on total fatty acids, u = unverifiable defined as ≤ 0.05%  
Fatty acid Cottonseed oil Linseed oil Safflower oil Sunflower oil Walnut oil 
8:0 u u u u u 
10:0 u u u u u 
12:0 u-0.2 u u u u 
14:0 0.6-0.1 u u-0.2 u-0.1 u-0.1 
16:0 21.4-26.4 4.0-6.0 5.3-8.0 2.6-5.0 6.0-8.0 
16:1 u-1.2 u-0.5 u-0.2 u-0.1 u-0.2 
17:0 u-0.1 U u-0.1 u-0.1 u-0.1 
17:1 u-0.1 U u-0.1 u-0.1 u 
18:0 2.1-3.3 2.0-3.0 1.9-2.9 2.9-6.2 1.0-3.0 
18:1 14.7-21.7 10.0-22.0 8.4-21.3 75.0-90.7 14.0-21.0 
18:2 46.7-58.2 12.0-18.0 67.8-83.2 2.1-17.0 54.0-65.0 
18:3 u-0.4 56.0-71.0 u-0.1 u-0.3 9.0-15.0 
20:0 0.2-0.5 u-0.5 0.2-0.4 0.2-0.5 u-0.3 
20:1 u-0.1 u-0.6 0.1-0.3 0.1-0.5 u-0.3 
20:2 u-0.1 u u u u 
22:0 u-0.6 u u-1.0 0.5-1.6 u-0.2 
22:1 u-0.3 u u-1.8 u-0.3 u 
22:2 u-0.1 u u u u 
24:0 u-0.1 u u-0.2 u-0.5 u 
24:1 u u u-0.2 u u 
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 3.2.5 Recommendations 
 
Fats are important energy storages for human and animal organisms, they 
should account for 25-30% of the daily energy intake.  
The amount of SFA should not exceed 10% of the total energy, MUFA should 
account for 10-15% of the total energy and PUFA should be around 7% of the 
total daily energy intake. Important is the ratio of w-6 to w-3 fatty acids, which 
shall amount to 5:1, but is in reality around 8-10:1 (ÖGE, 2011). 
Nevertheless, the maximal intake of w-3 fatty acids shall not exceed 2.5-3% of 
the total energy intake since they are able to result in bleedings or increased 
lipid oxidation in a very high dose. Furthermore they can unfavourably affect the 
function of leucocytes and the immune system (DGE, 2004). Increased 
requirements exist during pregnancy, lactation and growth period, after stages 
of stress and in old age. 
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 4 MATERIALS AND METHODS 
 
 4.1 Study design and population 
 
The EU project DIAPLANT is a program for a cross-border cooperation between 
Austria and Slovakia ("creating the future") with a view to investigate the 
influence of a plant oil and plant foods on biomarkers of secondary diseases of 
type 2 diabetics. The DIAPLANT-study is an epidemiological, prospective, 
randomized, controlled intervention study, which was approved by the Ethics 
Committee of the City of Vienna. 
 
The recruitment was done by three physicians at the health center Wien South 
of the Viennese regional medical insurance and a supplement in the journal 
"Diabetes- Info" of the Austrian Diabetic Association taking account of the 
inclusion and exclusion criteria. 
 
The following criteria had to be fulfilled: 
· Men and women with and without type 2 diabetes between 40 and 85 
years 
· glycated hemoglobin ≤ 9.5% 
· total cholesterol < 300 mg/dl 
· triglycerides in the serum < 500 mg/dl 
· creatinine < 2.5 mg/dl 
· steady medication concerning glucose, fat and uric acid metabolism 
· steady eating habits and physical activity 
· steady body weight 
 
Exclusion criteria were: 
· type 1 diabetes 
· people younger than 40 and older than 85 years 
· smoker 
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· pregnant and breastfeeding women 
· participation in other clinical studies 
· recently changed medication concerning glucose, fat and uric acid 
metabolism 
· intake of fish oil capsules or other fatty acids 
· cardiovascular diseases 
· hepatic diseases 
· chronic renal insufficiency 
· gastrointestinal malabsorption 
· organ transplantation 
· systemic steroids 
· cancer 
· HIV 
· intake of glitazone 
 
Interested people were invited to information sessions at the health center Wien 
South and informed about the health benefits of a diet rich in vegetables and 
the advantages of plant oils over animal fat. Afterwards the DIAPLANT study 
was presented and the study process was explained. Once the subjects had 
signed the statement of agreement, the randomization of the study participants 
in the intervention (Iv) and the information group (Inf) followed. Both the 
intervention and the information group included the four health states of the 
participants, namely insulin-dependent diabetes mellitus (IDDM), non-insulin-
dependent diabetes mellitus (NIDDM), impaired fasting glucose (IFG) and 
healthy (figure 3). Since some of the participants first allocated to the healthy 
group turned out to have impaired fasting blood glucose concentrations during 
the examinations an extra group (IFG) was formed. Different than originally 
planned this resulted in four groups with various health status. 
All subjects (Iv and Inf group) were informed about the advantages of a healthy 
diet. Additionally, the subjects of the intervention group received 300 g of 
vegetables and 25 ml of plant oil every day of the intervention phase, which 
lasted eight weeks. 
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Figure 3: Study design and classification of the participants 
 
 
 4.2 Study process over time 
 
During the study period (16 weeks) there were four blood collection dates. 
Blood was collected from fasting subjects, blood pressure was measured, urine 
was collected, a swab of buccal mucosa was done and anthropometric 
measurements were conducted at each examination for the entire study 
population. The last examination took place eight weeks after the end of the 
intervention. At T0 additionally the height was measured in order to determine 
the BMI (body mass index) of all the participants. 
Furthermore the subjects had to fill several questionnaires: a 24-hour protocol 
one day before each examination day, a quality of life questionnaire (QLQ) and 
a food frequency questionnaire (FFQ). Type 2 diabetics (IDDM and NIDDM) 
delivered their blood sugar profile. Study participants of the IDDM group also 
kept an insulin protocol.  
 
The intervention group was characterized by an eight-week lasting intervention 
phase (active phase), which was defined by two blood samplings, one after four 
weeks of intervention (T1) and one after eight weeks of intervention (T2). After 
Total 
n = 99
NIDDM 
n = 41 
IDDM 
n = 35 
IFG 
n = 12
Iv 
n = 30 
Inf 
n = 11
Iv 
n = 24
Inf 
n = 11
Iv 
n = 9
Inf 
n = 3
healthy 
n = 11 
Iv 
n = 5
Inf 
n = 6
30 
 
the active phase a further eight-week lasting period followed (T3), in which 
subjects did not get any oil and vegetables and returned to their original diet 
(figure 4). 
 
 
     16 weeks 
           Intervention         no intervention  
 
 
T0        T1             T2    T3  
    4 weeks          4 weeks    8 weeks 
 
 
Figure 4: Intervention phase and timing of the examinations 
 
 
Blood sampling, blood pressure, urine collection, swab of buccal mucosa, 
anthropometric measurements, QLQ, FFQ, 24-hour protocol, blood sugar 
profile, insulin protocol 
 
 
T0 Start of the study 
T1 after four weeks of intervention 
T2  after eight weeks of intervention 
T3 eight weeks after end of intervention 
 
 
 4.3 Characteristics of the intervention phase 
 
During the eight-week lasting intervention phase (active phase) participants 
consumed 300 g frozen vegetables of “Iglo” and 25 ml plant oil daily. Subjects 
were given a receipt book to demonstrate the right intake of the intervention oil 
and to facilitate the preparation of food. The recipes should demonstrate the 
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possibilities of the wide range of dishes based on vegetables. The required  
300 g of frozen vegetables per day could be consumed at once or spread 
throughout the day. Beyond that participants of the intervention group were 
asked to keep a food diary during the duration of the intervention. 
 
The following frozen products were provided by “Iglo”: 
· “Spinat passiert” 
· “Blattspinat Zwutschgerl” 
· “Cremespinat mit Mini-Rösti” 
· “Junge Fisolen” 
· “Kochsalat mit Erbsen” 
· “Broccoli”  
· “Kohlsprossen”  
· “Zarte Sojabohnen” 
· “Junge Erbsen”  
· “Karfiol Broccoli DUO” 
· “Buntes Gemüse Trio” 
· “Junges Sommergemüse” “Zarte Mischung”  
· “Suppengemüse”  
· “Röstgemüse Korsika” 
· “Röstgemüse Gärtnerin” 
 
The intervention oil was a nutritionally high-quality plant oil, which was rich in 
PUFA and contained a high amount of γ-tocopherol. Due to the fatty acid profile 
the oil should not be heated but stirred in ready-to-eat, cooked (vegetable soup, 
mashed potatoes, spinach) and cold foods (herb spread). When using the oil for 
making salads, it was important not to leave it in the marinade behind. 
 
The composition of the intervention oil, which was rich in w-3 and w-6 fatty acids 
and g-tocopherol, is shown in the tables 2 and 3: 
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Table 2: Fatty acid profile of the intervention oil 
% of total fatty acids C16:0 C18:0 C18:1n9c C18:1n7c C18:2n6c C18:3n3 
Mean value 7.28 2.06 16.4 0.95 61.76 11.49 
Standard deviation 0.09 0.07 0.99 0.03 1.00 0.43 
    
 
Table 3: Tocopherol content of the intervention oil 
mg/100 g oil g-tocopherol a-tocopherol 
Mean value 32.98 2.67 
Standard deviation 1.82 0.14 
 
 
 4.4 Study subjects 
 
The statement of agreement was signed by 120 people. At baseline the 
DIAPLANT collective consisted of 111 participants, 99 of them also completed 
the study. Lack of compliance, intolerance of intervention food and oil as well as 
hospitalizations were responsible for the loss of 10.8%. In table 4 general base 
data of the study population (n = 99) are shown. 
 
 
Table 4: Base data of the study population 
 
Intervention group 
MW±SD 
Information group 
MW±SD 
Total population 68 31 
IDDM 25 11 
NIDDM 29 11 
IFG 9 3 
Healthy 5 6 
Sex (male/female) 29/39 12/19 
Age (years) 65.76±7.29 61.65±6.66 
Body weight (kg) 89.38±16.41 90.02±18.98 
BMI (kg/m²) 32.50±5.71 32.21±7.03 
Duration of diabetes (years) 12.01±10.81 8.94±9.65 
HbA1c (%) 7.23±1.08 7.01±1.05 
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 4.5 Blood preparation 
 
Blood samples taken from fasting patients were put into centrifuge tubes which 
were coated with lithium-heparin or EDTA. After ten min. centrifugation at 3000 
rpm the plasma was aliquoted into Eppendorf tubes, purged with nitrogen and 
stored at -80°C until further analyses. Analyses of fatty acids were performed in 
heparin plasma. 
 
 
 4.6 Determination of the fatty acid profile 
 
 4.6.1 Method 
 
The plasma fatty acid profile in the plasma was determined by gas 
chromatography after previous hydrolysis under alkaline conditions with 
methanolic sodium hydroxide and esterification with boron trifluoride-methanol 
to fatty acid methyl esters (FAME). 
 
 4.6.2 Background 
 
Gas chromatography denotes a chromatographic technique for the segregation 
of mixtures of substances which can be vaporised without composition. The 
separation line is a column, where the stationary phase is adhered to the wall of 
the capillary and the mobile gas phase. 
Two substances can be separated when they show different retention times at 
the stationary phase. The separated substances are then detected by the 
detector and identified based on their individual retention time (Brinkert, 2005). 
 
 4.6.3 Reagents 
 
· Methanol p.a (Merck) 
· Sodium hydroxide (NaOH) (Riedel-de-Haën) 
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· Butylated hydroxytoluene (BHT) (Sigma) 
· Methanolic sodium hydroxide solution (1 g NaOH and 3 mg BHT in a 50 
ml round-bottom flask, padded with methanol and dissolved in ultrasonic 
bath) 
· Boron trifluoride-methanol, 14% (Sigma) 
· n-Hexan p.a (Merck) 
· 37-component standard SUPELCO 18919 AMP, F.A.M.E. Mix, C4-C24 
(Sigma) 
· PUFA No.2 SUPELCO 47015-u, Animal Source 
 
 4.6.4 Appliances 
 
· Pyrex test tubes with screw-cap and teflon-coated 
· glass test tubes 
· Shaker (IKA Labortechnik, KS 125 basic) 
· Water bath (40°C and 100°C) 
· Autosystem Gas chromatograph and gas chromatography vials 
 
 4.6.5 Implementation 
 
35 µl of heparinised plasma was transferred into Pyrex test tubes and laced with 
newly produced methanolic sodium hydroxide solution. Samples were 
saponified during five minutes boiling at 100°C in a water bath. After cooling to 
room temperature the released fatty acids were esterified by addition of 1 ml 
boron trifluoride-methanol and five minutes boiling at 100°C. 
After addition of 1 ml hexan it was shaked for five minutes. In order to gain all 
fatty acid methyl esters (FAME) this step was carried out four times. The hexan 
phase was transferred into glass test tubes and evaporated under nitrogen at 
40°C. 150 µl hexan were added to the dry FAME, transferred into gas 
chromatography vials and closed densely.  
FAME were separated by gas chromatography and detected by a flame 
ionization detector. 
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 4.6.6 Instrument adjustments 
 
· GC: Perkin Elmer Autosystem Gas Chromatograph 
· Detector: Flame ionization detector 
· Pillar: Restek 30 m, 0.25 mm ID, 0.2 µm df, 90% Biscyanoporopyl, 10% 
Phenylcyanopropylpolysiloxane 
· Temperature of injector: 250°C 
· Temperature of detector: 275°C 
· Carrier gas: Helium 
· Gas of detector: Hydrogen and air 
· Injection volume: 0.5 µl 
· Split: 1:50 
· Software: TotalChrom Workstation 
 
 4.6.7 Temperature program and duration 
 
Start temperature was 90°C and increased by 13°C/min until 155°C/min and 
further increased by 5°C/min up to 175°C. This temperature was held for 12 
minutes. Then the temperature increased by 2.9°C/min to 225°C. 
 
 4.6.8 Evaluation 
 
The qualitative evaluation was performed through the retention times of a 37-
component standard (figure). 
 
 4.6.9 Quality management 
 
In order to check the precision of the analyses a control plasma sample which 
was taken before the actual analyses, was analysed every workday. Every 
eighth sample was a control sample.  
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 4.7 Statistical evaluation 
 
Statistical evaluation was carried out with SPSS for Windows, Version 17.0. 
After exclusion of outliers, the data were checked for normal distribution with the 
Kolmogorov-Smirnov-Test. Data, which were normally distributed, were 
evaluated by the unpaired t-tests and one-way analysis of variance. Not 
normally distributed data were tested with the non-parametric Mann-Whitney-
Test or Kruskal-Wallis-Test. At T0 measures of correlations were realised with 
the Pearson’s correlation. Changes during the intervention were evaluated by 
repeated-measures analysis of variance (ANOVA). Time was used as repeating 
factor, treatment (information or intervention) and state of health (IDDM, 
NIDDM, healthy, IFG) as between subject factors.  
Statistical differences were considered to be significant at a value of p ≤ 0.05. 
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 5 RESULTS  AND DISCUSSION 
 
To make a statement about the subjects’ compliance the fatty acid profile in 
plasma was determined. The major fatty acids in the intervention oil were LA 
and ALA. Furthermore, the oil was rich in g-tocopherol (tables 2 and 3). 
 
 
 5.1 Important key findings at baseline 
 
 5.1.1 Gender-related differences of fatty acids 
 
At baseline (T0) there were no differences between men and women in those 
fatty acids shown on the left side of table 5. The right part of the table shows the 
fatty acids which were significantly different between men and women. 
 
 
 Table 5: Gender-related differences of fatty acids (% of total fatty acids) at baseline 
Fatty acid Mean value p Fatty acid Mean value p 
16:0          male 
female 
21.04±1.32 
21.27±1.80 0.503 
16:1n7      male 
female 
1.66±0.42 
2.01±0.63 0.010* 
18:1n9      male 
female 
21.43±2.64 
21.27±2.93 0.781 
18:0          male 
female 
7.11±0.65 
7.44±0.68 0.019* 
18:2n6      male 
female 
24.84±3.46 
24.99±4.31 0.860 
18:1n7      male 
female 
2.01±0.26 
1.85±0.28 0.004* 
18:3n3      male 
female 
0.55±0.29 
0.48±0.15 0.207 
18:3n6      male 
female 
0.38±0.13 
0.46±0.16 0.013* 
20:5n3      male 
female 
0.70±0.28 
0.70±0.31 0.968 
20:4n6      male 
female 
7.58±1.56 
6.89±1.51 0.033* 
22:5n3      male 
female 
0.54±0.10 
0.51±0.11 0.213 
   
22:6n3      male 
female 
1.68±0.45 
1.61±0.47 0.426 
   
SFA          male 
female 
30.01±1.51 
30.59±2.03 0.132 
   
MUFA       male 
female 
25.77±3.03 
25.74±3.46 0.965 
   
PUFA       male 
female 
38.08±3.76 
37.62±4.77 0.620 
   
* p-value ≤ 0.05 
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Differences in AA probably occurred due to men’s higher consumption of meat 
and meat products. According to Prättälä et al. (2007) men’s diet contains more 
often meat while women prefer fruits and vegetables. The data of the present 
study support this finding. The evaluation of food frequency questionnaires, 
completed within this study, also confirms that men consume more pork (44% 2-
3 times a week and 24% rarely) than women (31% 2-3 times a week and 36% 
rarely). g-linolenic acid (18:3n6), which is generated from LA by the d-6-
desaturase, is higher in women at baseline, indicating a higher enzyme activity 
in females (Watkins and German, 2008). 
There is no specific explanation for the gender-related differences of palmitoleic 
acid (16:1n7), stearic acid (18:0) and vaccenic acid (18:1n7) since these fatty 
acids occur in almost every fat and oil (European Food Information Council, 
2006). 
 
 5.1.2 Differences of fatty acids between the intervention and the 
information group 
 
There were no significant differences between the intervention and the 
information group at baseline in any of the fatty acids presented in table 6. 
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Table 6: Differences of fatty acids (% of total fatty acids) between the information and the 
intervention group at baseline 
Fatty acid Mean value p Fatty acid Mean value p 
16:0        Information 
Intervention 
20.83±1.46 
21.34±1.68 0.145 
18:3n6    Information 
Intervention 
0.45±0.15 
0.42±0.15 0.277 
16:1n7    Information 
Intervention 
1.88±0.53 
1.86±0.61 0.869 
18:3n3    Information 
Intervention 
0.51±0.19 
0.51±0.23 0.979 
18:0        Information 
Intervention 
7.35±0.69 
7.29±0.68 0.675 
20:4n6    Information 
Intervention 
7.29±1.68 
7.11±1.51 0.592 
18:1n9    Information 
Intervention 
21.26±2.69 
21.37±2.87 0.856 
20:5n3    Information 
Intervention 
0.68±0.24 
0.70±0.32 0.748 
18:1n7    Information 
Intervention 
1.91±0.28 
1.91±0.29 0.988 
22:5n3    Information 
Intervention 
0.53±0.10 
0.51±0.11 0.330 
18:2n6    Information 
Intervention 
24.86±3.77 
24.97±4.09 0.901 
22:6n3    Information 
Intervention 
1.62±0.39 
1.65±0.49 0.754 
SFA        Information 
Intervention 
30.06±1.66 
30.50±1.93 0.279 
MUFA     Information 
Intervention 
25.71±3.21 
25.77±3.34 0.940 
PUFA      Information 
Intervention 
37.95±3.75 
37.74±4.66 0.829 
   
 
 
 5.1.3 Differences of fatty acids between the various groups with 
different health status 
 
Table 7 summarises all the fatty acids that were significantly differed at baseline 
between IDDM, NIDDM, IFG and healthy subjects. 
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Table 7: Significant differences of fatty acids (% of total fatty acids) in the various groups with 
different health status at baseline 
Fatty acid Mean value p-value 
16:0         IDDM 
NIDDM 
healthy 
IFG 
20.91±1.44a 
21.86±1.45 
19.98±1.97a 
20.71±1.45 
0.001* 
18:1n9     IDDM 
NIDDM 
healthy 
IFG 
21.73±1.98 
21.92±2.75 
19.96±3.08 
19.28±3.78a 
0.010* 
18:2n6     IDDM 
NIDDM 
healthy 
IFG 
24.08±3.50 
23.99±3.19 
27.62±4.17ab 
28.23±5.08ab 
0.001* 
SFA         IDDM 
NIDDM 
healthy 
IFG 
30.07±1.63a 
31.08±1.86 
29.39±1.76a 
29.62±1.81 
0.007* 
MUFA      IDDM 
NIDDM 
healthy 
IFG 
26.31±2.32 
26.33±3.27 
24.43±3.82 
23.19±4.13ab 
0.011* 
PUFA       IDDM 
NIDDM 
healthy 
IFG 
37.32±3.41 
36.57±4.10 
40.05±4.35 
41.57±5.64ab 
0.001* 
      * p-value ≤ 0.05    
   a significantly different from NIDDM 
      b significantly different from IDDM 
 
 
The higher plasma levels of palmitic acid (16:0) and SFA in NIDDM compared to 
healthy subjects indicate a diet based on higher saturated fat intake. Especially 
diabetic subjects should reduce their intake of saturated fat due to the increased 
risk for cardiovascular diseases and stroke (Toeller, 2000). These findings go 
well together with the higher levels of LA and PUFA in the plasma of healthy and 
IFG subjects. These results indicate that the nutritional behaviour of healthy 
subjects is better than that of diabetics.   
d9-desaturase activity is known to be high in conditions like diabetes, 
atherosclerosis and obesity (Warnesjö et al., 2006). This explains the higher 
levels of oleic acid (18:1n9) and MUFA in subjects with IDDM and NIDDM. 
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 5.1.4 Correlations between PUFA and plasma lipids 
 
At baseline there was a positive correlation between the plasma PUFA content 
of all participants and HDL (r=0.524, p=0.000) and a negative correlation 
between PUFA and the ratio of total to HDL-cholesterol (r=-0.271, p=0.007). The 
Strong Heart Study has found the ratio of total to HDL-cholesterol to be a good 
predictor of cardiovascular risk in both men and women with type 2 diabetes (Lu 
et al., 2003). The study of Tapsell et al. (2004) demonstrated a significant 
decrease in the ratio of total to HDL-cholesterol in patients with diabetes by 
including 30g walnuts per day to the habitual diet, indicating the antiatherogenic 
potential of PUFA. 
 
Furthermore the correlation between PUFA and the HOMA Index for insulin 
resistance tended to be negative (r=-0.216, p=0.071) in diabetic subjects at 
baseline. These interesting findings point to the fact that PUFA might be 
supportive to decrease the blood glucose levels. On the other hand Mostad et 
al. (2006) found negative effects of a high fish oil intake (20 ml/day for nine 
weeks) on glucose metabolism. 
In the present study TG were negatively correlated with PUFA (r=-0.694, 
p=0.000) at baseline. Loschiavo et al. (1990) reported similar results in subjects 
consuming a diet with an elevated PUFA/SFA ratio. Conversely, in the present 
study the correlation between TG and SFA was positive, (r=0.546, p=0.000), 
which was also found by Cao et al. (2009). 
 
 
 5.2 Change over time in the intervention group 
 
 5.2.1 Total population 
 
In the total intervention group the following fatty acids changed significantly over 
time (table 8): 
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Table 8: Changes of fatty acids over time in the intervention group. * p value ≤ 0.05 
 
Fatty acid Change p-value 
16:0  0.000* 
16:1n7  0.000* 
18:1n9  0.000* 
18:1n7  0.004* 
18:2n6  0.000* 
18:3n3  0.000* 
22:6n3  0.018* 
SFA  0.000* 
MUFA  0.000* 
PUFA  0.000* 
 
 
The consumption of 25 ml PUFA rich plant oil, providing approximately 3 g ALA 
and 15 g LA, led to significant changes in SFA, MUFA and PUFA levels as well 
as in those fatty acids predominant in the plant oil, indicating a good dietary 
compliance. 
ALA significantly increased in the intervention group by 58.8% at T1 
(0.81±0.32%) and 62.8% at T2 (0.83±0.36%) compared with baseline levels 
(0.51±0.24%). Also LA significantly increased by 15.1% at T1 (28.62±4.53%) 
and 14.5% at T2 (28.47±4.28%) in comparison to baseline (24.87±4.11%). 
Consequently, PUFA also increased significantly by 8.8% at T1 (40.96±4.70%) 
and by 8.4% T2 (40.84±4.47%) compared to baseline (37.66±4.72%) (figure 5). 
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Figure 5: Changes (%) of ALA and LA compared to T0 during the intervention (T1 and T2).  
* Significant changes compared to T0. T0=0% 
 
 
The decreases of LA (25.26±4.05%) and ALA (0.57±0.25%) at T3 in comparison 
to baseline indicate that their changes were due to the intake of the intervention 
oil. It should be mentioned that the participants had to return the oil bottles at 
T2, so the intervention oil was not available any longer. 
Although LA and ALA are precursors of EPA and DHA, EPA remained constant 
and DHA decreased slightly (p=0.012) over time (T0=1.66±0.50, T1=1.53±0.42, 
T2=1.53±0.42). These findings are similar to the results of Almario et al. (2001). 
They found increased LA and ALA plasma concentrations after the addition of 
48 g walnuts to the habitual diet, whereas concentrations of EPA and DHA did 
not change. The authors suggest these findings as a result of the competition 
between LA and ALA for the d-6-desaturase.  
The plasma levels of AA did not show significant changes during the 
intervention. Other intervention studies demonstrated an increase in LA and a 
decrease in AA after interventions with a plant oil rich in PUFA (Karvonen et al., 
2002; Moloney et al., 2004). These findings are inconsistent with the results of 
Hodson et al. (2001), who showed an increase in both LA and AA after a shift 
from a diet rich in SFA to a diet rich in PUFA. During the SFA diet subjects used 
* 
* 
* * 
* * 
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butter for baking and cooking, consumed high-fat dairy foods and avoided the 
intake of vegetable oils. Within the w-6 PUFA diet participants used low-fat dairy 
foods, minimised the intake of foods high in SFA and avoided the consumption 
of butter. Furthermore they were provided with safflower oil (Hodson et al., 
2001). 
 
SFA significantly decreased over time in the intervention group 
(T0=30.53±1.95%, T1=29.56±2.00%, T2=29.68±1.78%) due to a significant 
reduction of palmitic acid (T0=21.40±1.69%, T1=20.52±1.89%, 
T2=20.61±1.59%). Also MUFA showed a significant decrease over time 
(T0=25.78±3.39%, T1=23.71±3.44%, T2=23.56±3.38%). In this respect the 
significant decreases of palmitoleic acid (T0=1.86±0.60%, T1=1.62±0.51%, 
T2=1.60±0.50%), vaccenic acid (T0=1.90±0.29%, T1=1.81±0.27%, 
T2=1.82±0.32%) and oleic acid (T0=21.18±2.75%, T1=19.44±2.71%, 
T2=19.42±2.79%) should be mentioned. The decrease in SFA and MUFA could 
result from the replacement of butter, margarine or oils rich in MUFA by the 
intervention oil, which contains high contents of PUFA.  
Results of Hodson et al. (2001) showed a significant decrease in palmitic acid 
after a replacement of SFA by a plant oil rich in PUFA. Changes in SFA were 
also found after supplementation with long-chain w-3 fatty acids in NIDDM 
subjects (Haban et al., 2000). Karvonen et al. (2002) chose camelina oil for the 
intervention and showed a significant decrease in palmitic acid and oleic acid. A 
compensatory decrease in palmitic acid and oleic acid to a higher PUFA intake 
and a significant reduction in SFA could also be shown after an addition of 48g 
walnuts to the habitual diet (Almario et al., 2001).  
Peck et al. (1996) observed a significant reduction of oleic acid in the plasma 
after an intervention with safflower oil.  
 
At T3 none of the investigated fatty acids showed any significance compared to 
baseline, indicating that the subjects of the intervention group returned to their 
usual diet. 
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As shown in the present study moderate changes in the diet by addition of 25 
ml PUFA rich plant oil lead to an elevation of PUFA and a reduction of SFA and 
MUFA. 
Several studies could demonstrate that a high fat intake, particularly if rich in 
SFA, is associated with impaired insulin sensitivity and secretion and the 
development of type 2 diabetes (Lovejoy, 1999; Marshall et al., 1997). Although 
studies on the role of PUFA in the prevention of type 2 diabetes are inconsistent 
(Jucker et al., 1999; Marshall et al., 1995; Meyer et al., 2001; Salméron et al, 
2001; Laaksonen et al., 2002), it is assumed that a higher PUFA intake, 
especially as replacement for SFA, is associated with a reduced risk for type 2 
diabetes (Hauner and Schulze, 2006).  
 
 5.2.2 IDDM and NIDDM 
 
The two predominant PUFA of the intervention oil, LA and ALA, significantly 
increased in the IDDM and NIDDM groups. Since both fatty acids were 
characteristic for the intervention oil, the increase confirms a good dietary 
compliance. In the IDDM group the LA significantly differed after four weeks of 
intervention. At T2 the levels were slightly lower than at T1 and therefore not 
significantly different from T0. Furthermore ALA significantly rose at T1 and T2 
(table 9). In patients with NIDDM, both LA and ALA were significantly different at 
T1 and T2 in comparison to T0. Furthermore 16:0 significantly decreased at T2 
(table 10). 
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Table 9: Fatty acid profile (% of total fatty acids) in the plasma of patients with IDDM in the 
intervention group. * Significant changes compared to T0. x Tendency of changes compared to 
T0 (p=0.05-0.1) 
Fatty acid T0 T1 T2 T3 
16:0 21.22±1.55 20.79±1.77 20.90±1.51 21.96±2.08 
16:1n7 1.95±0.52 1.75±0.51 1.65±0.43 1.99±0.52 
18:0 7.29±0.58 7.1±0.44 7.19±0.71 7.16±0.60 
18:1n9 21.67±2.03 20.17±2.60 19.94±2.59 21.78±2.04 
18:1n7 1.94±0.32 1.86±0.29 1.84±0.32 1.89±0.31 
18:2n6 24.59±3.67 28.31±4.08* 28.07±3.59x 24.21±3.10 
18:3n6 0.41±0.17 0.44±0.15 0.44±0.19 0.47±0.18 
18:3n3 0.43±0.19 0.74±0.22* 0.74±0.21* 0.50±0.12 
20:4n6 7.17±1.49 6.72±1.21 6.79±1.26 6.94±1.44 
20:5n3 0.65±0.25 0.66±0.25 0.77±0.44 0.78±0.34 
22:5n3 0.53±0.12 0.52±0.11 0.51±0.10 0.51±0.10 
22:6n3 1.42±0.23 1.37±0.28 1.43±0.39 1.47±0.40 
SFA 30.46±1.75 29.74±2.00 30.04±1.61 31.07±2.67 
MUFA 26.22±2.31 24.40±3.06 24.06±3.03 26.37±2.30 
PUFA 37.14±3.82 40.18±4.39 40.05±3.97 36.48±3.31 
 
 
Table 10: Fatty acid profile (% of total fatty acids) in the plasma of patients with NIDDM in the 
intervention group. * Significant changes compared to T0 
Fatty acid T0 T1 T2 T3 
16:0 21.97±1.56 20.93±1.75 20.77±1.42* 21.62±1.62 
16:1n7 1.84±0.62 1.61±0.52 1.62±0.55 1.82±0.49 
18:0 7.08±0.58 7.24±0.68 7.20±0.51 7.04±0.54 
18:1n9 21.74±2.76 19.84±2.60 19.82±2.82 21.09±2.99 
18:1n7 1.92±0.27 1.82±0.26 1.87±0.34 2.00±0.30 
18:2n6 23.75±3.28 27.49±4.43* 27.43±4.28* 24.16±3.91 
18:3n6 0.39±0.14 0.40±0.13 0.41±0.15 0.38±0.13 
18:3n3 0.51±0.16 0.86±0.27* 0.82±0.31* 0.60±0.26 
20:4n6 6.84±1.52 6.64±1.47 6.78±1.65 6.81±1.68 
20:5n3 0.68±0.30 0.71±0.27 0.73±0.28 0.70±0.26 
22:5n3 0.49±0.11 0.50±0.13 0.54±0.08 0.49±0.09 
22:6n3 1.75±0.51 1.61±0.44 1.55±0.33 1.61±0.39 
SFA 31.05±1.98 30.06±1.79 29.80±1.55 30.54±1.78 
MUFA 26.54±3.55 24.32±3.58 24.10±3.55* 26.98±4.23 
PUFA 36.23±4.32 39.85±4.66* 39.97±4.55* 36.82±4.96 
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In the IDDM group the relative increase of LA was 15.1% at T1 and 14.1% at T2 
(figure 6).  
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Figure 6: Changes of LA in the plasma of patients with IDDM in the intervention group.  
* Significant changes compared to T0. x Tendency of changes compared to T0 (p=0.05-0.1) 
 
 
ALA relatively increased by 72.1% at T1 and T2 compared with T0 (figure 7). 
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Figure 7: Changes of ALA in the plasma of patients with IDDM in the intervention group.  
* Significant changes compared to T0 
 
*
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In the NIDDM group LA increased by 13.6% at T1 and 13.4% at T2 (figure 8).  
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Figure 8: Changes of LA in the plasma of patients with NIDDM in the intervention group.  
* Significant changes compared to T0 
 
 
The rise of ALA accounted for 40.7% at T1 and 37.8% at T2 (figure 9). 
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Figure 9: Changes of ALA in the plasma of patients with NIDDM in the intervention group.  
* Significant changes compared to T0 
 
* *
* *
49 
 
 5.2.3 Healthy and IFG subjects 
 
Although the mean values of the characteristic fatty acids LA and ALA were 
higher at T1 and T2, no significant changes were observed in the healthy and 
the IFG-subjects (table 11 and 12). The reason could be the small sample 
number of only five healthy and nine IFG subjects and the large standard 
deviations. 
 
 
Table 11: Fatty acid profile (% of total fatty acids) in the plasma of healthy participants in the 
intervention group 
Fatty acid T0 T1 T2 T3 
16:0 20.39±2.51 18.51±1.88 18.84±1.62 19.27±1.05 
16:1n7 2.10±0.79 1.52±0.50 1.49±0.62 1.64±0.43 
18:0 7.56±1.14 7.48±1.08 7.32±0.92 7.36±0.87 
18:1n9 21.26±2.11 18.95±1.23 19.23±2.82 20.95±2.72 
18:1n7 1.81±0.29 1.81±0.29 1.85±0.22 1.87±0.20 
18:2n6 26.12±4.61 30.77±4.43 31.49±5.08 29.07±2.34 
18:3n6 0.55±0.20 0.44±0.20 0.44±0.28 0.51±0.26 
18:3n3 0.62±0.29 0.90±0.74 1.05±0.88 0.56±0.18 
20:4n6 6.41±1.28 7.09±2.04 6.31±1.32 6.66±1.61 
20:5n3 0.86±0.38 0.71±0.25 0.63±0.27 0.92±0.58 
22:5n3 0.57±0.10 0.54±0.08 0.49±0.06 0.54±0.12 
22:6n3 1.64±0.70 1.58±0.66 1.43±0.50 1.67±0.68 
SFA 29.90±1.99 27.58±1.79 27.74±1.96 28.13±1.04 
MUFA 25.93±2.74 22.89±1.28 23.21±3.09 25.08±2.55 
PUFA 38.79±3.97 43.73±2.21 43.54±3.55 41.82±1.59 
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Table 12: Fatty acid profile (% of total fatty acids) in the plasma of participants with IFG in the 
intervention group 
Fatty acid T0 T1 T2 T3 
16:0 20.32±1.23 19.38±1.86 20.36±1.99 20.62±2.26 
16:1n7 1.58±0.56 1.38±0.46 1.46±0.48 1.50±0.46 
18:0 7.91±0.71 7.74±0.57 7.65±0.48 7.61±0.70 
18:1n9 17.96±2.92 16.49±2.30 16.82±2.07 17.94±2.26 
18:1n7 1.81±0.26 1.67±0.21 1.57±0.14 1.67±0.18 
18:2n6 29.46±5.40 32.66±4.31 31.77±3.64 28.96±5.04 
18:3n6 0.42±0.14 0.40±0.17 0.45±0.20 0.39±0.17 
18:3n3 0.65±0.44 0.81±0.32 0.93±0.31 0.67±0.43 
20:4n6 7.85±1.47 7.20±1.16 7.13±1.82 7.58±1.74 
20:5n3 0.88±0.49 0.70±0.21 1.04±0.51 0.71±0.13 
22:5n3 0.53±0.07 0.52±0.10 0.57±0.05 0.53±0.07 
22:6n3 1.93±0.68 1.56±0.45 1.73±0.66 1.71±0.50 
SFA 29.26±1.89 28.52±2.05 29.53±2.38 29.99±3.12 
MUFA 21.81±3.32 20.16±2.87 20.50±2.44 21.75±2.53 
PUFA 43.53±4.76 45.30±4.18 44.35±4.25 42.82±5.43 
  
 
Pooling healthy and IFG subjects shows a significant increase of ALA at T2 
compared to T0. Increases of LA (T1 and T2) and ALA (T1) are indeed 
recognisable, but not significantly different from T0 (table 13). 
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Table 13: Fatty acid profile (% of total fatty acids) in the plasma of healthy and IFG participants 
in the intervention group. * Significant changes compared to T0 
Fatty acid T0 T1 T2 T3 
16:0 20.35±1.77 19.02±1.84 19.73±1.93 20.06±1.92 
16:1n7 1.78±0.68 1.43±0.46 1.47±0.52 1.55±0.43 
18:0 7.76±0.88 7.63±0.79 7.51±0.68 7.50±0.75 
18:1n9 19.23±3.04 17.44±2.27 17.75±2.58 19.10±2.79 
18:1n7 1.81±0.26 1.73±0.25 1.69±0.22 1.75±0.21 
18:2n6 28.07±5.16 31.87±4.27 31.66±4.08 29.01±3.98 
18:3n6 0.46±0.17 0.41±0.17 0.45±0.22 0.43±0.20 
18:3n3 0.64±0.37 0.84±0.49 0.97±0.57* 0.63±0.35 
20:4n6 7.29±1.53 7.16±1.47 6.81±1.64 7.23±1.68 
20:5n3 0.87±0.44 0.70±0.21 0.88±0.46 0.79±0.37 
22:5n3 0.55±0.08 0.53±0.09 0.54±0.06 0.53±0.09 
22:6n3 1.82±0.67 1.57±0.51 1.61±0.60 1.70±0.55 
SFA 29.51±1.87 28.16±1.94 28.84±2.33 29.27±2.63 
MUFA 23.39±3.65 21.21±2.69 21.54±2.92 23.03±2.96 
PUFA 41.71±4.92 44.70±3.52 44.04±3.86 42.44±4.28 
 
 
 5.3 Change over time in the information group 
 
 5.3.1 Total population 
 
In the fatty acid profiles of subjects of the information group no significant 
changes occurred. 
 
 5.3.2 IDDM and NIDDM 
 
The fatty acid profile of subjects with IDDM did not significantly change over 
time (table 14) as well as that of subjects with NIDDM (table 15). 
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Table 14: Fatty acid profile (% of total fatty acids) in the plasma of patients with IDDM in the 
information group 
Fatty acid T0 T1 T2 T3 
16:0 20.55±1.25 21.25±1.90 21.45±1.73 21.21±1.73 
16:1n7 2.03±0.39 2.08±0.35 2.19±0.52 2.23±0.53 
18:0 7.02±0.45 7.20±0.40 7.17±0.45 7.16±0.60 
18:1n9 22.15±2.14 22.14±2.22 22.27±1.91 23.37±2.01 
18:1n7 2.07±0.28 2.01±0.28 1.93±0.22 2.09±0.28 
18:2n6 22.36±2.52 22.38±2.86 22.86±3.31 22.29±3.10 
18:3n6 0.48±0.15 0.56±0.17 0.55±0.17 0.51±0.14 
18:3n3 0.46±0.16 0.47±0.18 0.47±0.14 0.45±0.20 
20:4n6 8.16±1.40 8.05±1.45 7.69±1.08 7.72±1.05 
20:5n3 0.72±0.13 0.79±0.20 0.82±0.25 0.69±0.22 
22:5n3 0.57±0.10 0.56±0.05 0.58±0.08 0.59±0.10 
22:6n3 1.75±0.25 1.76±0.32 1.68±0.40 1.60±0.29 
SFA 29.31±1.22 30.45±2.06 30.53±1.66 30.16±1.95 
MUFA 26.90±2.57 26.89±2.63 27.08±2.35 28.35±2.39 
PUFA 36.93±2.64 36.26±2.55 36.42±2.87 25.63±2.98 
     
 
Table 15: Fatty acid profile (% of total fatty acids) in the plasma of patients with NIDDM in the 
information group 
Fatty acid T0 T1 T2 T3 
16:0 21.42±1.08 21.96±1.66 21.60±1.25 21.95±1.39 
16:1n7 1.74±0.63 1.97±0.83 1.80±0.76 2.00±0.84 
18:0 7.65±0.71 7.33±0.33 7.37±0.75 7.27±0.58 
18:1n9 21.06±1.56 22.56±1.74 22.23±2.34 21.81±1.59 
18:1n7 1.90±0.20 1.87±0.23 2.02±0.27 1.97±0.20 
18:2n6 25.10±2.66 24.20±2.29 24.78±3.23 24.37±3.80 
18:3n6 0.46±0.16 0.48±0.22 0.40±0.15 0.46±0.16 
18:3n3 0.48±0.11 0.54±0.17 0.43±0.12 0.49±0.14 
20:4n6 7.35±1.97 6.75±1.81 7.32±1.84 6.90±1.65 
20:5n3 0.69±0.34 0.56±0.22 0.54±0.14 0.63±0.21 
22:5n3 0.51±0.11 0.44±0.11 0.47±0.08 0.51±0.11 
22:6n3 1.58±0.53 1.46±0.55 1.48±0.39 1.47±0.62 
SFA 30.95±1.49 31.36±2.04 30.84±0.87 31.24±1.92 
MUFA 25.34±2.12 27.01±2.16 26.64±2.81 26.41±2.10 
PUFA 38.11±2.93 36.18±3.01 37.21±3.14 36.85±3.34 
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 5.3.3 Healthy and IFG subjects 
 
The fatty acid profile of healthy subjects did not significantly differ between T0 
and any time point during (T1) or at the end the intervention (T2) (table 16). In 
the IFG group the ALA significantly decreased at T1 (table 17), maybe due to 
the high baseline level. 
 
 
Table 16: Fatty acid profile (% of total fatty acids) in the plasma of healthy participants in the 
information group             
Fatty acid T0 T1 T2 T3 
16:0 19.63±1.55 19.58±1.49 19.82±1.56 20.14±1.59 
16:1n7 1.95±0.70 2.02±0.76 2.20±1.11 2.28±1.13 
18:0 7.62±0.70 7.44±0.75 7.17±0.96 7.32±0.87 
18:1n9 18.88±3.52 20.16±3.75 19.97±3.43 20.21±2.81 
18:1n7 1.72±0.34 1.80±0.31 1.89±0.31 1.86±0.32 
18:2n6 28.88±3.69 28.28±3.41 27.55±3.56 26.56±3.23 
18:3n6 0.44±0.23 0.46±0.16 0.43±0.12 0.46±0.17 
18:3n3 0.46±0.15 0.51±0.19 0.52±0.10 0.59±0.15 
20:4n6 6.48±1.36 6.53±1.37 6.47±1.63 6.55±1.33 
20:5n3 0.57±0.17 0.73±0.29 0.70±0.22 0.76±0.23 
22:5n3 0.50±0.05 0.53±0.08 0.54±0.07 0.55±0.10 
22:6n3 1.73±0.29 1.65±0.35 1.54±0.44 1.59±0.30 
SFA 28.96±1.59 28.76±1.04 28.87±1.02 29.39±1.03 
MUFA 23.17±4.35 24.63±4.70 24.75±4.92 25.05±4.16 
PUFA 41.09±4.73 40.83±4.91 39.83±5.20 39.14±4.34 
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Table 17: Fatty acid profile (% of total fatty acids) in the plasma of participants with IFG in the 
information group. * Significant changes compared to T0 
Fatty acid T0 T1 T2 T3 
16:0 21.62±1.80 21.85±0.95 21.99±1.26 21.65±0.99 
16:1n7 1.61±0.28 1.78±1.88 1.76±0.40 1.73±0.08 
18:0 6.62±0.78 6.94±0.47 6.59±0.76 6.91±0.86 
18:1n9 22.79±4.01 22.14±2.17 20.01±1.85 20.25±0.85 
18:1n7 1.77±0.11 1.64±0.11 1.67±0.11 1.63±0.24 
18:2n6 25.06±3.77 24.57±3.26 26.40±3.48 25.24±3.43 
18:3n6 0.38±0.04 0.47±0.11 0.44±0.15 0.47±0.22 
18:3n3 0.91±0.28 0.51±0.15* 0.68±0.20 0.60±0.26 
20:4n6 5.59±0.40 6.30±1.06 6.52±1.42 6.38±0.43 
20:5n3 0.59±0.17 0.71±0.32 0.61±0.19 0.59±0.07 
22:5n3 0.56±0.13 0.64±0.14 0.57±0.11 0.59±0.10 
22:6n3 1.18±0.12 1.40±0.33 1.36±0.29 1.26±0.14 
SFA 30.57±1.41 31.10±0.90 31.02±1.10 31.04±1.32 
MUFA 26.89±4.31 26.25±2.21 24.09±2.27 24.29±0.86 
PUFA 36.36±4.86 36.65±1.42 38.46±2.55 37.00±2.92 
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 6 CONCLUSION 
 
Diabetes mellitus is one of the most common chronic diseases worldwide, with 
a continuously increasing number in prevalence and incidence. In 2011 366 
million people were affected by type 2 diabetes. Estimations assume that this 
number will increase to 552 million people by 2030. In Austria about 571.000 of 
the adult population currently suffer from diabetes (IDF, 2011). 
Due to the great number of patients and the high risk for coronary heart 
diseases and other long-term complications nutrition programs are of great 
importance. Therefore a human intervention study entitled “DIAPLANT” was 
performed at the Department of Nutritional Sciences at the University of Vienna 
within the Emerging Field "Oxidative Stress and DNA Stability". The study 
aimed to investigate the influence of a plant oil rich in PUFA and vegetables on 
biomarkers of secondary diseases in type 2 diabetics. The total study 
population consisted of 99 healthy and diabetic participants.  
The aim of the present master thesis was to investigate the influence of an 
eight-week intervention with plant oil and vegetables on the fatty acid profile in 
the plasma of type 2 diabetics. The plasma fatty acid profile was determined by 
gas chromatography. The primary objective of this work was to verify the 
compliance. Furthermore, the plasma levels of several fatty acids between type 
2 diabetics, healthy subjects and those with abnormal fasting glucose 
concentrations were compared. Moreover, changes due to the intervention and 
the different effects on the various health states were investigated. 
 
At baseline 
At baseline, there were no significant differences between the intervention and 
the information group in any of the investigated fatty acids. Most fatty acids did 
not show any gender-related differences. Those differing can be explained by a 
higher meat consumption of men (AA) and a higher enzyme activity in females 
(g-linolenic acid) (Prättälä et al. 2007; Watkins and German, 2008). 
Comparisons between the various groups with different health status (IDDM, 
NIDDM, healthy and IFG subjects) showed significant differences in several 
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fatty acids. Higher plasma levels of palmitic acid and SFA in diabetics indicate a 
usual diet higher in saturated fat, which is accompanied with the lower levels of 
LA and PUFA. These results assume a better nutritional behaviour of healthy 
subjects. Higher levels of oleic acid and MUFA in diabetic subjects can be 
explained by a higher activity of the d-9-desaturase. The activity of this enzyme 
is known to be high in conditions like diabetes, atherosclerosis and obesity 
(Warnesjö et al., 2006). 
 
Significant correlations for all subjects were found between PUFA and plasma 
lipids. There was a positive correlation between PUFA and HDL (r=0,524, 
p=0.000). The correlation between PUFA and the ratio of total to HDL-
cholesterol was negative (r=-0,271, p=0.007). This association is important as 
the ratio of total to HDL-cholesterol is a good predictor of cardiovascular risk in 
subjects with type 2 diabetes (Lu et al., 2003). TG were negatively correlated 
with PUFA (r=-0.694, p=0.000). Opposite to this the correlation between TG and 
SFA was positive (r=0.546, p=0.000). A trend towards a negative correlation (r=-
0.216, p=0.071) was observed between plasma PUFA and the HOMA Index for 
insulin resistance in diabetic subjects. 
Similar correlations as found in the present intervention study were reported in 
several other studies (Tapsell et al., 2004; Loschiavo et al., 1990; Cao et al., 
2009). Due to these findings one can assume that a diet containing high-quality 
fat has positive impacts on glucose and fat metabolism. 
 
Changes over time 
The consumption of 25 ml PUFA rich plant oil led to significant changes in SFA, 
MUFA and PUFA levels as well as their predominant forms (palmitic acid, 
palmitoleic acid, vaccenic acid, oleic acid, LA, ALA) in the intervention group, 
indicating a good dietary compliance. These significant changes result from the 
replacement of butter, margarine or oils rich in MUFA by the PUFA-rich 
intervention oil. 
ALA significantly increased in the intervention group by 58.8% at T1 and 62.8% 
at T2 compared with baseline levels. LA significantly increased by 15.1% at T1 
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and 14.5% at T2 in comparison to baseline. Consequently, PUFA increased 
significantly by 8.8% at T1 and by 8.4% T2 compared with baseline.  
Results of other studies showed similar changes of the fatty acid profiles after 
an intervention with an oil or food rich in PUFA (Hodson et al., 2001; Haban et 
al., 2000; Karvonen et al., 2002; Peck et al., Almario et al., 1996). 
 
In the IDDM group the relative increase of LA was 15.13% at T1 and 14.11% at 
T2. ALA relatively increased by 72.09% at T1 and T2 compared with T0.  
In the NIDDM group LA increased by 13.61% at T1 and 13.42% at T2. The rise 
of ALA accounted for 40.70% at T1 and 37.81% at T2. 
In the healthy and IFG-subjects no significant changes could be observed due 
to the small sample number and the large standard deviations. 
 
The fatty acid profiles of the information group did not change significantly. 
 
As shown in the present study moderate changes in the diet by addition of 25 
ml PUFA rich plant oil lead to an elevation of PUFA and a reduction of SFA and 
MUFA in the plasma of healthy and diabetic subjects.  
Although studies on the role of PUFA in the prevention of type 2 diabetes are 
inconsistent (Jucker et al., 1999; Marshall et al., 1995; Meyer et al., 2001; 
Salméron et al, 2001; Laaksonen et al., 2002), it is assumed that a higher PUFA 
intake, especially as replacement for SFA, is associated with a reduced risk for 
type 2 diabetes (Hauner and Schulze, 2006).  
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 7 SUMMARY 
 
Background: Diabetes mellitus is one of the most common chronic diseases 
worldwide, with a continuously increasing number of prevalence and incidence. 
In 2011 the estimated number of adults living with diabetes has reached 366 
million, representing 8.3% of the global adult population. 
A higher PUFA intake, especially as replacement for SFA, is associated with a 
reduced risk for type 2 diabetes. 
 
Methods: The study investigated the effect of an intervention with a plant oil rich 
in w-3 and w-6 fatty acids and vegetables on biomarkers of secondary diseases 
of diabetic patients. Therefore 99 diabetic and non-diabetic persons were 
randomly assigned to either the information or the intervention group. 
Participants of the intervention group received 25 ml of plant oil and 300 g 
vegetables each day for eight weeks. After blood sampling and blood 
preparation the plasma fatty acid profile was determined by gas 
chromatography. The aim of this master thesis was to investigate the influence 
of the eight-week intervention with a plant oil and vegetables on the fatty acid 
profile in the plasma of type 2 diabetics in order to prove their study compliance. 
 
Results: The intervention with 25 ml plant oil rich in w-3 and w-6 fatty acids and 
300 g vegetables per day showed significant increases in LA, ALA and PUFA in 
the plasma of the participants, confirming a good dietary compliance. 
Simultaneously, SFA and MUFA significantly decreased. 
 
Conclusions: 
Intake of PUFA-rich plant oil significantly increased PUFA in the plasma of 
diabetic subjects and led at the same time to significant reductions of SFA and 
MUFA. 
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 8 ZUSAMMENFASSUNG 
 
Hintergrund: Diabetes mellitus ist weltweit eine der am häufigsten auftretenden 
chronischen Erkrankungen, wobei Prävalenz und Inzidenz stetig ansteigen. 
2011 betrug die geschätzte Anzahl an erwachsenen Diabetikern 366 Millionen, 
entsprechend 8,3% der erwachsenen Weltbevölkerung.  
Eine erhöhte Aufnahme von mehrfach ungesättigten Fettsäuren, besonders als 
Ersatz für gesättigte Fettsäuren, wird mit einem verringerten Risiko für Typ 2 
Diabetes assoziiert. 
 
Methoden: Die Studie untersuchte den Effekt einer Intervention mit einem w-3 
und w-6 fettsäurereichen Pflanzenöl und Gemüse auf die 
Sekundärerkrankungen von Diabetikern. Dazu erfolgte eine Randomisierung 
von 99 diabetischen und nicht-diabetischen Studienteilnehmern  in eine 
Informations- und eine Interventionsgruppe. Die Teilnehmer der 
Interventionsgruppe erhielten 25 ml Pflanzenöl und 300 g Gemüse pro Tag. 
Nach Blutabnahmen und –aufbereitung wurde das Fettsäuremuster im Plasma 
mittels Gaschromatographie bestimmt. 
Das Ziel dieser Arbeit war es, den Einfluss einer achtwöchigen Intervention mit 
dem Pflanzenöl und Gemüse auf das Fettsäuremuster im Plasma von Typ-2 
Diabetikern zu untersuchen und deren Studiencompliance zu bestätigen. 
 
Ergebnisse: Die Intervention mit 25 ml eines Pflanzenöls, das reich an w-3 und 
w-6 Fettsäuren war, sowie 300 g Gemüse pro Tag zeigte signifikante 
Steigerungen von Linolsäure, a-Linolensäure und der Summe an mehrfach 
ungesättigten Fettsäuren im Plasma der Studienteilnehmer. Dies bestätigt eine 
gute Ernährungscompliance. Gleichzeitig wurde eine signifikante Reduktion der 
gesättigten und einfach ungesättigten Fettsäuren beobachtet. 
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Conclusio: 
Die Einnahme eines Pflanzenöls, das reich an ungesättigten Fettsäuren ist, 
erhöht mehrfach ungesättigte Fettsäuren im Plasma von Diabetikern signifikant 
und führt auch zu signifikanten Reduktionen von gesättigten und einfach 
ungesättigten Fettsäuren. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
61 
 
 9 REFERENCES 
 
Almario RU, Vonghavaravat V, Wong R, Kasim-Karakas SE: Effects of walnut 
 consumption on plasma fatty acids and lipoproteins in combined 
 hyperlipidemia. Am J Clin Nutr 2001; 74/1: 72-79. 
 
American Diabetes Association: Diagnosis and Classification of Diabetes 
Mellitus. Diabetes Care 2012; 35/1: 64-71. 
 
American Diabetes Association: Nutrition Recommendations and Interventions for 
Diabetes. Diabetes Care 2008; 31/1: 61-78. 
 
American Diabetes Association: Gestational Diabetes Mellitus: Diabetes Care 2004; 
27/1: 88-90. 
 
Biesalski HK, Grimm P: Lipide. In: Taschenatlas Ernährung, 5. Auflage. Georg Thieme 
Verlag KG, Stuttgart, 2011; 80-81. 
 
Bitsch I, Bitsch R: Essentielle Fettsäuren. In: Handbuch für Lebensmittelchemiker, 3. 
Auflage (Frede W, Herausgeber). Springer Medizin Verlag, Heidelberg, 2010; 
1108. 
 
Brinkert T: Grundlagen der Gaschromatographie. Institut für Spektrochemie und 
 angewandte Spektroskopie Dortmund, 2005: 3-5. 
 
Calder PC: Dietary fatty acids and lymphocyte functions. Proceedings of the Nutrition 
Society 1998; 57: 487-502. 
 
Cao Y, Mauger DT, Pelkman CL, Zhao G, Townsend SM, Kris-Etherton PM: Effects of 
moderate (MF) versus lower fat (LF) diets on lipids and lipoproteins: a meta-
analysis of clinical trials in subjects with and without diabetes. Journal of Clinical 
Lipidology 2009; 3: 19–32. 
 
62 
 
Capito K, Hansen S, Hedeskov C, Thams P: Fat-inducedchanges in mouse pancreatic 
islet secretion, insulin biosynthesis and glucose metabolism. Acta Diabetol 
1992; 28: 193–198. 
 
Chalkley SM, Hettiarachchi M, Chisholm DJ, Kraegen EW: Long-term high-fat feeding 
leads to severe insulin resistance but not diabetes in Wistar rats. Am J Physiol 
Endocrinol Metab 2002; 282: 1231–1238. 
 
De Caterina R, Madonna R, Bertolotto A, Schmidt EB: n-3 Fatty acids in the 
 Treatment of Diabetic Patients. Diabetes Care 2007; 30: 1012-1026. 
 
Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 
diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346: 393-
403. 
 
De Munter JS, Hu FB, Spiegelman D, Franz M, van Dam RM: Whole grain, bran, and 
germ intake and risk of type 2 diabetes: a prospective cohort study and 
systematic review. PLoS Med. 2007; 4: 261. 
 
Deutsche Gesellschaft für Ernährung: Ernährungstherapie bei Diabetes. DGEInfo 
07/2008.  
Internet: http://www.dge.de/modules.php?name=News&file=article&sid=865 
(25.1.12). 
 
Deutsche Gesellschaft für Ernährung: Referenzwerte für die Nährstoffzufuhr, 2004. 
Internet: 
http://www.dge.de/modules.php?name=Content&pa=showpage&pid=3&page=1
1 (25.1.12). 
 
Deutsche Gesellschaft für Ernährung: Zuckerkrankheit ist gut durch Ernährung 
beeinflußbar. DGE-aktuell 18/1998.  
Internet: http://www.dge.de/modules.php?name=News&file=article&sid=28 
(25.1.12) 
 
 
63 
 
Doenecke D, Koolman J, Fuchs G, Gerok W: Fette und Fettstoffwechsel. In: Karlsons 
Biochemie und Pathobiochemie, 15. Auflage. Georg Thieme Verlag KG, 
Stuttgart, 2005; 275-276, 288, 566. 
 
European Food Information Council: Fette, 2006. Internet: 
http://www.eufic.org/article/de/expid/basics-fette (5.2.12). 
 
Feskens EJM, Virtanen SM, Räsänen L, Tuomilehto J, Stengard J, Pekkanen J, 
 Nissinen A, Kromhout D: Dietary factors determining diabetes and 
 impaired glucose tolerance. Diabetes Care 1995; 18: 1104-1112. 
 
Fiebig HJ, Matthäus B: Fette. In: Handbuch für Lebensmittelchemiker, 3. Auflage 
(Frede W, Herausgeber). Springer Medizin Verlag, Heidelberg, 2010; 615-616. 
 
Fiebig HJ: Fettsäurezusammensetzung wichtiger pflanzlicher und tierischer 
 Speisefette und -öle. Deutsche Gesellschaft für Fettwissenschaft, 2011. 
 Internet: http://www.dgfett.de/material/fszus.htm (25.1.12). 
 
Giacco R, Cuomo V, Vessby B, Uusitupa M, Hermansen K, Meyer BJ, Riccardi G, 
Rivellese AA: Fish oil, insulin sensitivity, insulin secretion and glucose tolerance 
in healthy people: is there any effect of fish oil supplementation in relation to the 
type of background diet and habitual dietary intake of n-6 and n-3 fatty acids? 
Nutr Metab Cardiovasc Dis 2007; 17: 572-580. 
 
Gremlich S, Bonny C, Waeber G, Thorens B: Fatty acids decrease IDX-1 expression in 
rat pancreatic islets and reduce GLUT2, glucokinase, insulin, and somatostatin 
levels. J Biol Chem 1997; 272: 30261–30269. 
 
Haban P, Zidekova E, Klvanova J: Supplementation with long-chain n-3 fatty acids in 
non-insulin-dependent diabetes mellitus (NIDDM) patients leads to the lowering 
of oleic acid content in serum phospholipids. Eur J Nutr 2000; 39/5: 201-206. 
 
Hauner H, Schulze M: Fettkonsum und Prävention des Typ 2 Diabetes Mellitus. 
Deutsche Gesellschaft für Ernährung e. V., Bonn 2006: 75-94. 
 
64 
 
Hauner H, Schulze M: Kohlenhydratzufuhr und Prävention des Diabetes mellitus Typ 2. 
Deutsche Gesellschaft für Ernährung e. V., Bonn 2011: 58-74. 
 
Heckel C: Einfluss von Omega-3-Fettsäuren aus Algen auf das Fettsäuremuster und 
auf Knochenparameter beim Pony. Dissertation, LMU München, Tierärztliche 
Fakultät 2009: 26-28. Internet: http://edoc.ub.uni-
muenchen.de/10969/1/Heckel_Claudia.pdf (25.1.12). 
 
Heinze E, Torn H, Wabitsch M, Wudy S, Sorgo W, Homoki J: Bestimmung von 
Insulinresistenz und Insulinsensitivität bei Kindern und Jugendlichen. 
Monatsschrift Kinderheilkunde 2002; 150: 1095-1100. 
 
Hodson L, Skeaff CM, Chisholm WAH: The effect of replacing dietary saturated fat with 
polyunsaturated or monounsaturated fat on plasma lipids in free-living young 
adults. European Journal of Clinical Nutrition 2001, 55: 908-915. 
 
Holness MJ, Greenwood GK, Smith ND, Sugden MC: Diabetogenic Impact of Long-
Chain w-3 Fatty Acids on Pancreatic β-Cell Function and the Regulation of 
Endogenous Glucose Production. Endocrinology 2003, 144(9): 3958-3968. 
 
Hu FB, van Dam RM, Liu S: Diet and risk of type II diabetes: the role of types of fat and 
carbohydrate. Diabetologia 2001; 44: 805-817. 
 
International Diabetes Federation: IDF Diabetes Atlas, 5th edn. Brussels, Belgium, 
2011. Internet: http://www.idf.org/diabetesatlas (25.1.12). 
 
Jenkins DJA, Kendall CW, Axelsen M, Augustin LS, Vuksan V: Viscous and nonviscous 
fibres, nonabsorbable and low glycaemic index carbohydrates, blood lipids and 
coronary heart disease. Curr Opin Lipidol. 2000; 11: 49–56. 
 
Jenkins DJA, Kendall CW, Augustin LSA, Martini MC, Axelsen M, Faulkner D, Vidgen 
E, Parker T, Lau H, Connelly PW, Teitel J, Singer W, Vandenbroucke AC, Leiter 
LA, Josse RG: Effect of wheat bran on glycemic control and risk factors for 
cardiovascular disease in type 2 diabetes. Diabetes Care 2002; 25: 1522–1528. 
 
65 
 
Joint FAO/WHO Expert Consultation on Fats and Fatty Acids in Human Nutrition: 
Interim Summary of Conclusions and Dietary Recommendations on Total Fat & 
Fatty Acids. WHO, Geneva, 2008. 
 
Jucker BM, Cline GW, Barucci N, Shulman GI: Differential effects of safflower oil versus 
fish oil feeding on insulin-stimulated glycogen synthesis, glycolysis, and 
pyruvate dehydrogenase flux in skeletal muscle: a 13C nuclear magnetic 
resonance study. Diabetes 1999; 48(1): 134-140. 
 
Karvonen HM, Aro A, Tapola NS, Salminen I, Uusitupa MIJ, Sarkkinen ES: Effect of 
Alpha-linolenic acid-rich Camelina sativa oil on serum fatty acid composition 
and serum lipids in hypercholesterolemic subjects. Metabolism: Clinical and 
Experimental 2002; 51: 1253-1260. 
 
Kraegen EW, Clark PW, Jenkins AB, Daley EA, Chisholm DJ, Storlien LH: 
Development of muscle insulin resistance after liver insulin resistance in high-
fat-fed rats. Diabetes 1991; 40: 1397–1403. 
 
Kubota N, Tobe K, Terauchi Y, Eto K, Yamauchi T, Suzuki R, Tsubamoto Y, Komeda K, 
Nakano R, Miki H, Satoh S, Sekihara H, Sciacchitano S, Lesniak M, Aizawa S, 
Nagai R, Kimura S, Akanuma Y, Taylor SI, Kadowaki T: Disruption of insulin 
receptor substrate 2 causes type 2 diabetes because of liver insulin resistance 
and lack of compensatory β-cell hyperplasia. Diabetes 2000; 49: 1880–1889. 
 
Laaksonen DE, Lakka TA, Lakka HM, Nyyssonen K, Rissanen T, Niskanen LK, 
Salonen JT: Serum fatty acid composition predicts development of impaired 
fasting glycaemia and diabetes in middle-aged men. Diabet Med 2002; 19: 456-
464. 
 
Lebovitz HE: Insulin resistance: definition and consequences. Exp Clin Endocrinol 
Diabetes 2001; 109/2: 135-48. 
 
Lee D: Obesity, 2010.  
Internet: http://www.medicinenet.com/obesity_weight_loss/article.htm (25.1.12). 
 
66 
 
Leitzmann C, Müller C, Michel P, Brehme U, Triebel T, Hahn A, Laube H: Ernährung in 
Prävention und Therapie, 3. Auflage. Hippokrates Verlag, Stuttgart, 2009; 312-
322. 
 
Löffler G: Stoffwechsel von Triacylglycerinen und Fettsäuren. In: Biochemie & 
Pathobiochemie, 8. Auflage (Löffler G, Petrides PE, Heinrich PC, Herausgeber). 
Springer Medizin Verlag, Heidelberg, 2007; 419-425. 
 
Loschiavo C, Ferrari S, Aprili F, Grigolini L, Faccini G, Maschio G: Modification of serum 
and membrane lipid composition induced by diet in patients with chronic renal 
failure. Clin Nephrol. 1990; 34/6: 267-271. 
 
Lovejoy JC: Dietary fatty acids and insulin resistance. Curr  Atheroscler Rep 1999; 1: 
215–220. 
 
Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK, Howard WJ, Robbins DC, 
Howard BV: Non-HDL cholesterol as a predictor of cardiovascular disease in 
type 2 diabetes: the strong heart study. Diabetes Care 2003; 26: 16-23. 
 
Manco M, Calvani M, Mingrone G: Effects of dietary fatty acids on insulin sensitivity 
and secretion. Diabetes, Obesity and Metabolism 2004; 6/6: 402-413. 
 
Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, 
Natale S, Forlani G, Melchionda N: Nonalcoholic fatty liver disease: a feature of 
the metabolic syndrome. Diabetes 2001; 50: 1844–1850. 
 
Marshall JA, Hoag S, Shetterly S, Hamman RF: Dietary fat predicts conversion from 
impaired glucose tolerance to NIDDM – The San Luis Valley Diabetes Study. 
Diabetes Care 1994; 17: 50-56. 
 
Marshall JA, Bessesen DH, Hamman RF: High saturated fat and low starch and fibre 
are associated with hyperinsulinemia in a non-diabetic population: the San Luis 
Valley Diabetes Study. Diabetologia 1997; 40: 430–438. 
 
67 
 
McGraw-Hill Concise Dictionary of Modern Medicine: Insulin Sensitivity, 2002. Internet: 
http://medical-dictionary.thefreedictionary.com/insulin+sensitivity (25.1.12). 
 
Meyer KA, Kushi LH, Jacobs DR, Folsom AR: Dietary fat and incidence of type 2 
diabetes in older Iowa women. Diabetes Care 2001; 24: 1528-1535. 
 
Miebach M: Untersuchung von Zusammenhängen zwischen pflanzlichen Emissionen 
und pflanzeninternen Signalmolekülen und Enzymaktivitäten. Dissertation, 
RWTH Aachen University, Fakultät für Mathematik, Informatik und 
Naturwissenschaften 2008: 13. Internet: http://darwin.bth.rwth-
aachen.de/opus3/volltexte/2009/2980/pdf/Miebach_Marco.pdf (25.1.12). 
 
Moloney F, Yeow TP, Mullen A, Nolan JJ, Roche HM: Conjugated linoleic acid 
supplementation, insulin sensitivity, and lipoprotein metabolism in patients with 
type 2 diabetes mellitus. Am J Clin Nutr 2004; 80: 887-895. 
 
Mostad IL, Bjerve KS, Bjorgaas MR, Lydersen S, Grill V: Effects of n-3 fatty acids in 
subjects with type 2 diabetes: reduction of insulin sensitivity and time-
dependent alteration from carbohydrate to fat oxidation. Am J Clin Nutr 2006; 
84: 540-550. 
 
Österreichische Gesellschaft für Ernährung: Fette, 2011.  
Internet: www.oege.at/php/current/content.php?c=2114 (25.1.12) 
 
Peck LW, Monsen ER, Ahmad S: Effect of three sources of long-chain fatty acids on the 
plasma fatty acid profile, plasma prostaglandin E2 concentrations, and pruritus 
symptoms in hemodialysis patients. Am J Clin Nutr 1996; 64: 210-214. 
 
Pegorier JP, Le May C, Girard J: Control of gene expression by fatty acids.  
J Nutr 2004; 134: 2444-2449. 
 
Pi-Sunyer X: Do glycemic index, glycemic load, and fibre play a role in insulin 
sensitivity, disposition index, and type 2 diabetes? Diabetes Care 2005; 28: 
2978–2979. 
 
68 
 
Prättälä R, Paalanen L, Grinberga D, Helasoja V, Kasmel A, Petkeviciene J: Gender 
differences in the consumption of meat, fruit and vegetables are similar in 
Finland and the Baltic countries. Eur J Public Health 2007; 17/5: 520-525. 
 
Rehner G, Daniel H: Das Fettgewebe als Energiespeicher und Drehscheibe des 
Lipidstoffwechsels. In: Biochemie der Ernährung, 3. Auflage. Spektrum 
Akademischer Verlag, Heidelberg, 2010; 500-503. 
 
Riccardi G, Rivellese AA, Giacco R: Role of glycemic index and glycemic load in the 
healthy state, in prediabetes, and in diabetes. Am J Clin Nutr 2008, 87: 269-
274. 
 
Rivellese AA, Lilli S: Quality of dietary fatty acids, insulin sensitivity and type 2 
 diabetes. Biomed Pharmacother, 2003; 57 (2): 84-87. 
 
Robertson MD, Bickerton AS, Dennis AL, Vidal H, Frayn KN: Insulinsensitizing effects 
of dietary resistant starch and effects on skeletal muscle and adipose tissue 
metabolism. Am J Clin Nutr. 2005; 82: 559–567. 
 
Roden M: Diabetes mellitus - Definition, Klassifikation und Diagnose. Wien Klin 
Wochenschr 2009; 121: 5-7. 
 
Salmerón J, Hu FB, Manson JE, Stampfer MJ, Colditz GA, Rimm EB, Willett WC: 
Dietary fat intake and risk of type 2 diabetes in women. Am J Clin Nutr 2001; 73: 
1019-1026. 
 
Schulze MB, Schulz M, Heidemann C, Schienkiewitz A, Hoffmann K, Boeing H: Fibre 
and Magnesium Intake and Incidence of Type 2 Diabetes: A Prospective Study 
and Meta-analysis. Arch Intern Med. 2007; 167: 956–65. 
 
Song Y, Manson JE, Buring JE, Liu S: A prospective study of red meat consumption 
and type 2 diabe-tes in middle-aged and elderly women: the Women's Health 
Study. Diabetes Care 2004; 27: 2108-2115. 
 
69 
 
Stein DT, Stevenson BE, Chester MW et al.: The insulinotropic potency of fatty acids is 
influenced pro-foundly by their chain length and degree of saturation. J Clin 
Invest 1997; 100: 398–403. 
 
Storlien LH, Baur LA, Kriketos AD, et al.: Dietary fats and insulin action. Diabetologia 
1996; 39: 621–631. 
 
Tapsell LC, Gillen LJ, Patch CS, Batterham M, Owen A, Baré M, Kennedy M:  Walnuts 
in Diet Improves HDL Cholesterol-Total Cholesterol Ratio: Conclusions. 
Diabetes Care 2004; 27/12. 
 
Toeller M: Wichtiges zur Ernährungsbehandlung. In: Diabetes Heute,  Schriftenreihe 
der Deutschen Diabetes Union e.V. 2000. Internet: http://www.diabetes-
heute.uni-duesseldorf.de/ernaehrung/texte/index.html?TextID=1055 (4.2.12). 
 
Trautwein EA: w-3 Fettsäuren. In: Praxishandbuch Functional Food (Erbersdobler AF, 
Meyer AH, Herausgeber). B. Behr’s Verlag GmbH Co. KG, Hamburg, 1999. 
 
Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, 
Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, 
Aunola S, Cepaitis Z, Moltchanov V, Hakumäki M, Mannelin M, Martikkala V, 
Sundvall J, Uusitupa M: Prevention of type 2 diabetes mellitus by changes in 
lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 
344: 1343-1350. 
 
Van Dam RM, Willett WC, Rimm EB, Stampfer MJ, Hu FB: Dietary fat and meat intake 
in relation to risk of type 2 diabetes in men. Diabetes Care 2002; 25: 417-424. 
 
Vessby B, Uusitupa M, Hermansen K, Riccardi G, Rivellese AA, Tapsell LC, Nälsén C, 
Berglund L, Louheranta A, Rasmussen BM, Calvert GD, Maffetone A, Pedersen 
E, Gustafsson IB, Storlien LH: Substituting dietary saturated for 
monounsaturated fat impairs insulin sensitivity in healthy men and women: The 
KANWU Study. Diabetologia, 2001; 44(3): 312-9. 
 
 
70 
 
Vostrowsky O: Fettsaeuren. In: Chemie der Naturstoffe. Institut für Organische Chemie 
II der Friedrich-Alexander-Universität Erlangen-Nürnberg, 2005: 1, 5. Internet: 
http://www.chemie.uni-erlangen.de/vostrowsky/natstoff/01Fettsaeuren.pdf 
(25.1.12). 
 
Warensjö E, Ohrvall M, Vessby B: Fatty acid composition and estimated desaturase 
activities are associated with obesity and lifestyle variables in men and women. 
Nutrition, Metabolism & Cardiovascular Diseases 2006; 16/2: 128-136. 
 
Warnotte C, Gilon P, Nenquin M, Henquin JC: Mechanisms of the stimulation of insulin 
release by saturatedfatty acids. A study of palmitate effects in mouse beta-cells. 
Diabetes 1994; 43: 703–711. 
 
Watkins SM, German JB: Unsaturated Fatty Acids. In: Food Lipids: Chemistry, 
Nutrition, and Biotechnology, Third Edition (Akoh CC, Min DB, Herausgeber). 
CRC Press, 2008; 519. 
 
Weickert MO, Pfeiffer AF.: Metabolic effects of dietary fibre consumption and 
 prevention of diabetes. J Nutr. 2008, 138: 439–442. 
 
Wilcox G: Insulin and Insulin Resistance. Clin Biochem Rev. 2005; 26/2: 19–39. 
 
Wild S, Roglic G, Green A, Sicree R & King H: Global prevalence of diabetes: estimates 
for the year 2000 and projections for 2030. Diabetes Care 2004, 27: 1047-1053. 
 
Zahradnik HP: Eicosanoide (Prostaglandine und Leukotriene) – Grundlagen und Klinik. 
In: Archives of Gynecology and Obstetrics 1991, 250/1-4; 3. 
 
 
 
 
 
 
 
 
LEBENSLAUF 
 
Persönliche Daten     
 
Name:   Kristina Paller 
Geburtsdatum:  1. Juli 1986 
Staatsbürgerschaft: Österreich 
 
Ausbildung 
 
2010 –  2012 Masterstudium der Ernährungswissenschaften an der 
Universität Wien 
Mai 2010  Abschluss des Bakkalaureatsstudiums der 
Ernährungswissenschaften 
2006 – 2010  Bakkalaureatsstudium der Ernährungswissenschaften an 
der Universität Wien 
2004 – 2007 1. Studienabschnitt Internationale Betriebswirtschaft an der 
Wirtschaftsuniversität Wien 
Juni 2004  Matura am Bundesgymnasium Eisenstadt 
 
Berufliche Erfahrungen 
 
Feb. 2011  Praktikum in der Apotheke zum Granatapfel der 
Barmherzigen Brüder (Eisenstadt) 
Sept. 2010 Praktikum Diätologie im Orthopädischen Spital Speising 
Juli – Aug. 2009 Praktikum im Schloss Esterhazy Management (Eisenstadt) 
Juli – Aug. 2008 Praktikum im Schloss Esterhazy Management (Eisenstadt) 
Juli – Aug. 2007 Praktikum im Schloss Esterhazy Management (Eisenstadt) 
Nov. 2006 –   Marketing des Schloss Esterhazy Management (Eisenstadt) 
März 2007    
Juli – Aug. 2006 Praktikum im Schloss Esterhazy Management (Eisenstadt) 
Juli – Aug. 2005 Praktikum im Schloss Esterhazy Management (Eisenstadt) 
